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Abstract
Mesenchymal stem cells (MSCs) are emerging donor grafts for bone regeneration in dentistry. MSCs are
phenotypically and functionally skeletal site- specific based on extensive studies using human and rodent
MSCs but there is paucity of information on canine MSCs (cMSCs) and their regenerative applications in
veterinary dentistry. We hypothesized that cMSCs are functionally skeletal-site specific and that mandible
cMSCs (M-cMSCs) are highly osteogenic relative to femur cMSCs (F-cMSCs). Trabecular bone samples
were obtained from mandible and femur of 2 healthy beagle dogs (ages: 3 weeks, females). Primary M-cMSCs
and F-cMSCs were established in culture. Using early passage cells, colony-forming units (CFU), cell
proliferation and population doubling capacity were assessed. Using established induction culture conditions,
in vitro osteogenesis, chondrogenesis, adipogenesis, and neurogenesis were also assessed. Western blotting
and real time PCR were used to assess the following osteogenic markers: alkaline phosphatase (ALP), bone
sialoprotein (BSP), osteocalcin (OCN) and osteopontin (OPN). Chondrogenesis was assessed using pellet
culture method and histologic sections were stained with Alcian blue; adipogenically induced-cultures were
stained with Oil Red O. Neural differentiation was evaluated using morphological analysis and
immunostaining to nestin and βIII-tubulin antibodies. Furthermore, in vivo osteogenesis was assessed using
the mouse model of in vivo bone regeneration. Transplants were harvested at 6, 8 and 12 weeks for
histological analysis.The M-cMSCs demonstrated 1.5 to 2 fold increases in cell proliferation (p =0.006) and
life span (five more passages of survival) relative to F-cMSCs. Similar pattern was displayed by M-cMSCs
based on expression levels of BSP (14 days p=0.05), ALP (14 days p= 0.004) and OCN (14 days p= 0.03) but
OPN levels were not significantly different. Adipogenesis based on number of stained lipid droplets per unit
area in M-cMSCs was significant higher than F-cMSCs (p=0.007) and chondrogenic response was also
significant higher in M-cMSCs compared with F-cMSCs (4 weeks p= 0.009). Canine MSCs induced
substantial in vivo bone formation. The canine MSCs phenotypic and functional properties are site-
dependent as the M-cMSCs were apparently more responsive to multi-lineage differentiation relative to F-
cMSCs. While the sample size in this study is limited, our findings are still consistent with previous studies
using human, mouse and rat MSCs for site-to-site comparative characterizations (Akintoye et al, 2006;
Yoshimura et al, 2007; Aghaloo et al, 2010; Lee et al, 2011). Additionally, it is imperative to further confirm
these in a larger sample size and in other dog breeds since dogs exhibit an extremely wide range of body
physique. New information will advance our understanding of pre-clinical applications of orofacial MSCs as
donor graft materials for oral bone regeneration.
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ABSTRACT 
Mesenchymal stem cells (MSCs) are emerging donor grafts for bone 
regeneration in dentistry. MSCs are phenotypically and functionally skeletal site-
specific based on extensive studies using human and rodent MSCs but there is 
paucity of information on canine MSCs (cMSCs) and their regenerative 
applications in veterinary dentistry. We hypothesized that cMSCs are functionally 
skeletal-site specific and that mandible cMSCs (M-cMSCs) are highly osteogenic 
relative to femur cMSCs (F-cMSCs). 
Trabecular bone samples were obtained from mandible and femur of 2 healthy 
beagle dogs (ages: 3 weeks, females). Primary M-cMSCs and F-cMSCs were 
established in culture. Using early passage cells, colony-forming units (CFU), cell 
proliferation and population doubling capacity were assessed. Using established 
induction culture conditions, in vitro osteogenesis, chondrogenesis, 
adipogenesis, and neurogenesis were also assessed. Western blotting and real 
time PCR were used to assess the following osteogenic markers: alkaline 
phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN) and osteopontin 
(OPN). Chondrogenesis was assessed using pellet culture method and histologic 
sections were stained with Alcian blue; adipogenically induced-cultures were 
stained with Oil Red O. Neural differentiation was evaluated using morphological 
analysis and immunostaining to nestin and βIII-tubulin antibodies. Furthermore, 
in vivo osteogenesis was assessed using the mouse model of in vivo bone 
regeneration. Transplants were harvested at 6, 8 and 12 weeks for histological 
analysis. 
The M-cMSCs demonstrated 1.5 to 2 fold increases in cell proliferation (p = 
0.006) and life span (five more passages of survival) relative to F-cMSCs. Similar 
pattern was displayed by M-cMSCs based on expression levels of BSP (14 days 
p= 0.05), ALP (14 days p= 0.004) and OCN (14 days p= 0.03) but OPN levels 
were not significantly different. Adipogenesis based on number of stained lipid 
droplets per unit area in M-cMSCs was significant higher than F-cMSCs (p= 
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0.007) and chondrogenic response was also significant higher in M-cMSCs 
compared with F-cMSCs (4 weeks p= 0.009). Canine MSCs induced substantial 
in vivo bone formation. 
The canine MSCs phenotypic and functional properties are site-dependent as the 
M-cMSCs were apparently more responsive to multi-lineage differentiation 
relative to F-cMSCs. While the sample size in this study is limited, our findings 
are still consistent with previous studies using human, mouse and rat MSCs for 
site-to-site comparative characterizations (Akintoye et al, 2006; Yoshimura et al, 
2007; Aghaloo et al, 2010; Lee et al, 2011). Additionally, it is imperative to further 
confirm these in a larger sample size and in other dog breeds since dogs exhibit 
an extremely wide range of body physique. New information will advance our 
understanding of pre-clinical applications of orofacial MSCs as donor graft 
materials for oral bone regeneration.  
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1 INTRODUCTION 
1.1 Development of craniofacial, axial, and appendicular skeleton  
One of the hallmarks that distinguish vertebrates from invertebrates is the 
formation of bones, their associated cartilages, and joints. The first sign of 
skeletal development is formation of mesenchymal condensations, in which 
mesenchymal progenitor cells aggregate at future skeletal locations. These 
mesenchymal cells arise from different cell lineages. The mesenchyme that gives 
rise to the axial skeletal elements (i.e., vertebral column, ribs, and sternum) 
originates from the sclerotomal portion of the mesodermal somites, whereas the 
appendicular skeleton (pectoral girdles, upper and lower limbs, pelvis) is derived 
from the mesenchyme of the lateral plate mesoderm. The developmental origin 
of the craniofacial skeleton is more complex. Some cranial bones (e.g., the 
bones making up the roof and much of the base of the skull) are mesodermal in 
origin, but the facial bones and some other cranial bones arise from 
mesenchyme derived from the ectodermal neural crest. Skeletal formation 
progresses through two major mechanisms: intramembranous and endochondral 
ossification. The type of ossification and anatomic properties of the bones are 
determined by the location of each skeletal element. Consequently, the deep 
skeletal parts of the body typically first appear as cartilaginous models of the 
bones that will ultimately be formed. At specific periods during embryogenesis, 
the cartilage is replaced by true bone through the process of endochondral 
ossification. By contrast, during intramembranous ossification, the superficial 
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bones of the face and skull are formed by direct ossification of mesenchymal 
cells without an intermediate cartilaginous stage (Helms and Schneider, 2003; 
Carlson, 2014; Clifford et al, 2013).  
Mammalian craniofacial skeleton is a complex structure of bones and cartilages 
that is generally divided in two main components: the neurocranium and the 
viscerocranium. The neurocranium encloses and supports the brain and cranial 
sense organs. It comprises the skull vault and base. The viscerocranium 
provides the structural scaffolding for sight, olfaction and, together with the 
mandible, mastication (Lawson, 2008). Frontal, parietal, and a part of the 
occipital bones form the skull vault. The frontal bones are developed from cranial 
neural crest cells (NCCs), while others are mostly derived from mesoderm cells. 
These bones are interconnected by cranial sutures which are the primary sites of 
osteogenesis during skull development. The skull vault is formed through 
intramembranous ossification. Ethmoid, sphenoid, basioccipital bones, and parts 
of the temporal bones build the cranial base. The anterior-most skull base is 
derived from cranial NCCs, while the posterior region comes from paraxial 
mesoderm. Contrasting with other craniofacial skeletal components, bones from 
the skull base develop through endochondral ossification (Clifford et al, 2013; 
McBratney-Owen et al, 2008). 
Early craniofacial development is characterized by several massive migrations 
and displacements of cells and tissues. Bones that come into being the 
viscerocranium are derived from cranial NCCs. These cells develop in dorsal 
midline ectoderm of the midbrain and the rhombencephalon (or hindbrain), in a 
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number of transversal swellings called rhombomeres, undergo an epithelial to 
mesenchymal transition, delaminate, and then migrate ventrolaterally between 
the ectoderm and endoderm. While the rostral cranial NCCs develop the 
frontonasal skeleton and the skull vault, NCCs from each rhombomere, take 
distinct pathways to populate different pharyngeal arches (PA). NCCs from 
rhombomeres 1 and 2 migrate into the first pharyngeal arch and the frontonasal 
process. This structure gives rise to the incus and malleus of the ears, the 
mandible, and the maxilla. The frontonasal process gives rise to tissues in the 
upper half of the face, including the forehead, nose, eyes, and philtrum. NCCs 
from rhombomeres 3 and 4 migrate into the second pharyngeal arch, which gives 
rise to the stapes bone of the middle ear, the styloid process of temporal bone, 
and a part of the hyoid bone. The third arch gives rise to structures related to the 
hyoid bone and upper pharynx, while the fourth arch forms certain muscles and 
cartilages of the larynx and lower pharynx (Fig. 1) (Helms, 2003; Carlson, 2014; 
Clifford, et al, 2013).  
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Development of the axial and appendicular skeleton: the intra-embryonic 
mesoderm of each side of the forming notochord and neural tube thickens to 
form a longitudinal column of para-axial mesoderm. By the end of the third week 
of the embryonic development, the para-axial mesoderm divides into paired 
bodies called somites, located bilaterally to the neural tube. At the fourth week, 
ventromedial cells migrate toward the notochord to form sclerotome 
Figure 1 
 
Adapted  from Clifford et al, 2013.Primer on the metabolic bone diseases and 
disorders of mineral metabolism. 
Cranial NCC migration and NCC-derived cartilage and bones: (A) NCCs go through 
epithelial-mesenchymal transition and migrate ventrolaterally from rhombomeres (R) 
to populate pharyngeal arches (PA). NCCs in R3 and R5 merge with streams of 
NCCs from neighboring rhombomeres. Bones and cartilage derived from each PA 
are listed. (B) Facial and frontal bones are derived from NCCs. Posterior skull base 
and vault are mostly derived from somatic mesoderm. 
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(mesenchyme). Proteins secreted by notochord and neural tube floor plate 
induce sclerotome formation. Once induced, sclerotome cells express the 
transcription factor PAX1 that initiates a cascade of cartilage and bone forming 
genes for vertebral column development. The first pair of somites develops a 
short distance posterior to the cranial end of the notochord, and the rest of the 
somites develop caudally. Around 38 pairs of somites form during the somite 
period of development, from days 20 to 30. The final number is 42 to 44 pairs. 
Each somite becomes differentiated into ventromedial sclerotome (for vertebrae 
and ribs), myotome (muscles) and dermatome (skin). In addition to the paraxial 
region, the mesoderm forms lateral somatic plates that form all cartilages and 
bones of appendicular skeleton. By the end of week four, limb buds are visible 
and each one consists of a mass of mesenchyme derived from the somatic 
mesoderm, covered by a layer of ectoderm. At the tip of each limb bud, 
ectodermal cells form an apical ectodermal ridge, which promotes growth and 
development of the limbs in the proximo-distal axis (Moore, 2008) (Fig. 2 and 3). 
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Figure 2 
Adapted from Copyright © 2007 Lippincott Williams & Wilkins 
A third week human blastocyst with three germ layers: movement of 
the mesodermal cells between 17 and 21 days of development. 
Figure 3 
Adapted from Mark, H. Skeletal development: vertebral column and limbs, University of 
Toledo 
Skeletal development vertebral column and limbs: origin of axial and 
appendicular skeleton from scleretome and lateral plate mesoderm. 
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1.2 Bone tissue  
    
1.2.1 General features            
Bone is one of the most metabolically active connective tissues in the vertebrate 
organisms. It is a highly vascularized and well innervated mineralized tissue. 
Bone provides structural support and facilitates mobility by providing levers for 
muscle attachment. Bone also protects vital structures, serves as reservoirs for 
minerals and acid-base homeostasis, and is a vital site for hematopoiesis (Buck, 
et al, 2011; Fernandez, et al, 2006). Each particular bone of any organism 
constantly experiences modeling during life to adapt to changing biomechanical 
forces, as well as remodeling to remove old, micro-damaged bone and replace it 
with new, mechanically stronger bone to help preserve bone strength (Clarke, 
2008). 
The two main structural types of bones are cortical and cancellous or trabecular 
bone. The ratio of cortical to trabecular bone is different for each bone and 
skeletal site within a specific bone. For example, this ratio is 50:50 in the human 
femoral head (Clarke, 2008). Cortical bone, with a porosity of 5-10%, provides 
bone its compressive strength as well as a maximum resistance to torsion and 
bending (Buck, et al, 2011). Cancellous bone has a high metabolic activity and 
remodeling rate. It can adapt readily to mechanical stimuli and changes in 
loading forces (Buckwalter, et al, 1995). Cortical and trabecular bone are 
normally formed in a lamellar pattern in which collagen fibrils are tightly packed in 
sheets with uniform distribution of osteocytes and bone matrix. The mechanism 
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by which osteoblasts lay down collagen fibrils in a lamellar pattern is unknown, 
but lamellar bone has a significant strength as a result of the alternating 
orientations of collagen fibrils (Buck et al, 2011; Fernandez et al, 2006; Clarke, 
2008). The arrangement of these lamellae determines whether the bone is 
cortical or cancellous. In the cortical bone, lamellae are concentric and parallel to 
the long axis of the bone. They surround central Haversian canals forming the 
major structural unit of cortical bone: the osteon. Multiple cell processes, or 
canaliculi, from osteocytes extend in a radial pattern from the central canal, 
allowing diffusion of nutrients through the bone matrix (Jepsen, 2009; Buck et al, 
2011). Cancellous or trabecular bone is formed by a network of bone lamellae, 
delimiting areolar cavities inside which the bone marrow is found. In this bone, 
lamellae are arranged in semicircular shapes called packets, and this kind of 
structure gives cancellous bone remarkable surface area which is an important 
feature in the rate of bone graft incorporation (Clarke, 2008; Jepsen, 2009). 
The periosteum is a fibrous connective tissue sheath that covers the external 
surface of bone and is attached to the outer cortex via thick collagenous fibers 
called “Sharpey’s fibers”. It contains blood vessels, nerve fibers, and osteoblasts 
and osteoclasts. Additionally, it provides an attachment site for some ligaments 
and tendons. The periosteum is a structure with two layers: a dense, hypocellular 
outer layer that continues into joint capsules and interconnects adjacent bones 
and an inner layer, the cambium, which contains osteoprogenitor cells and a 
vascular plexus. The endosteum is a membranous structure covering the inner 
surface of cortical bone, trabecular bone, and the blood vessel canals 
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(Volkmann’s canals) present in bone. The endosteum is relatively cellular 
containing osteoprogenitor cells, as well blood vessels (Clarke, 2008; Buckwalter 
et al, 1995; Buck et al, 2011). Both cortical and trabecular bone contain 
specialized cells, organic matrix and mineral phase (Fernandez et al, 2006). 
1.2.2 Bone cells 
Several cell types can be found in bone (Table 1). Bone cells are located within 
the bone tissue itself or in the conjunctive stroma of the bone marrow, which is 
rich in mesenchymal stem cells. These cells differentiate into osteoprogenitor 
cells that form the osteoblasts and osteocytes, while osteoclasts arise from 
hematopoietic stem cells (Buck et al, 2011; Fernandez et al, 2006). 
 
 
 
 
 
 
 
 
Osteoblasts originate from the mesenchymal stem cells of the bone marrow, 
endosteum, periosteum, and perivascular pericytes (Canfield et al, 2000). 
Osteoblast precursors change shape from spindle-shaped osteoprogenitors to 
large cuboidal differentiated osteoblasts on bone matrix surfaces after pre-
osteoblasts stop proliferating. Active mature osteoblasts that synthesize bone 
Table 1 Bone cells 
Adapted from Buck et al, 2011; Fernandez et al, 2006 
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matrix have large nuclei, enlarged Golgi structures, and substantial rough 
endoplasmic reticulum (Clarke, 2008). Osteoblasts synthesize the organic matrix 
or osteoid material at a rate of 2 to 3 μm per day, and express a characteristic 
enzyme, alkaline phosphatase (ALP), which orchestrates mineralization at a rate 
of 1-2 μm per day.  They can also express other osteoblastic markers such as 
bone sialoprotein, osteopontin, and osteonectin during the process of 
osteoblastic differentiation. It is accepted that they: (i) synthesize the collagen 
and non-collagen proteins of the organic bone matrix, (ii) direct the arrangement 
of the extracellular matrix fibrils, (iii) contribute to the mineralization of the osteoid 
material, due to the alkaline phosphatase, (iv) mediate in the resorption carried 
out by the osteoclasts, through the synthesis of specific cytokines, and (v) 
synthesize growth factors (Fernandez et al, 2006). Usually after 10 weeks, 
osteoblasts can disappear through apoptosis, become transformed into bone 
lining cells or into osteocytes (15%) (Aubin and Liu, 1996). Therefore, flattened 
bone-lining cells are thought to be quiescent osteoblasts that form the 
endosteum on trabecular and endosteal surfaces and underlie the periosteum on 
the mineralized surface. Osteoblasts and lining cells are found in close proximity 
and joined by adherents junctions. Cadherins are calcium-dependent 
transmembrane proteins that are integral parts of adherent junctions and 
together with tight junctions and desmosomes join cells together by linking their 
cytoskeletons (Shin, 2000). 
Osteoclasts are large multinucleated cells, rich in mitochondria and vacuoles 
responsible for bone resorption, located in shallow depressions on bone surfaces 
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called Howship lacunae (Buck et al, 2011; Fernandez et al, 2006; Clarke 2008). 
These cells originate from the bone marrow hematopoietic stem cells known as 
‘Granulocyte-Macrophage Colony-Forming Units’ (GM-CFU), which are 
precursors of macrophages and monocytes (Fernandez et al, 2005; Compston et 
al, 2013). In the process of osteoclastogenesis, marrow stromal cells and 
osteoblasts play a critical role since they secrete two essential cytokines: 
macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear 
factor-kB ligand (RANKL), which is a ligand situated on the surface of the 
osteoblasts and pre-osteoblasts (Teitelbaum et al, 2003; Fernandez et al, 2006; 
Clarke, 2008; Clifford et al, 2013). RANKL, previously called osteoclast 
differentiation factor (Simone et al, 1997), is a transmembrane cytokine 
belonging to the tumor necrosis factor family (TNF), and interacts with its 
receptor, RANK, expressed by pre-osteoclasts. This interaction initiates 
osteoclastic differentiation and activity to promote resorption. M-CSF is required 
for the proliferation, survival, and differentiation of osteoclast precursors, as well 
as osteoclast survival and cytoskeletal rearrangement required for bone 
resorption (Clarke, 2008; Fernandez et al, 2006). In addition, osteoprotegerin 
(OPG) is a soluble protein secreted by osteoblasts and pre-osteoblasts that binds 
RANKL with high affinity to inhibit its action at the RANK receptor (Cohen, 2006). 
When OPG and RANKL bind together, the union between RANK and RANKL is 
inhibited, and thus the osteoclastic differentiation is also inhibited. For this reason 
OPG, RANK and RANKL are important regulators of osteoclastogenesis 
(Fernandez et al, 2006). The other factors and cytokines that regulate osteoclast 
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formation and activity, include interleukin-1, interleukin-6, parathyroid hormone, 
1,25-dihidroxyvitamin D, and calcitonin (Boyle et al, 2003; Blair and Athanasou, 
2004). The membrane of osteoclasts has two special characteristics: a ruffled 
border, where resorption takes place, and a clear area rich in microfilaments, 
with integrins that serve as an anchor to the matrix. When the resorption process 
starts, the osteoclasts move towards the area to be resorbed and then 
immediately adhere to the mineralized bone surface with the ruffled border and 
sealing the edges of the area with the integrins. The β1 family of integrin 
receptors in osteoclasts, particularly αvβ3, recognizes the Arg-Gly-Asp sequence 
in the collagen and other proteins of the osteoid matrix. At this level the pH is 
acidic since osteoclasts secrete hydrogen ions, generated by carbonic anhydrase 
II and proteolytic enzymes such as collagenases, metalloproteases, cathepsin K, 
and glucuronidase.These enzymes initiate bone resorption by the solubilization 
of, first the organic and, then the mineral matrix. Osteoclasts create a sealing 
zone that surrounds and isolates the acidified resorption compartment from the 
surrounding bone surface (Ross and Teitelbaum, 1995; Vaananen et al, 2000). 
Bone resorption can be blocked by disruption of either the ruffled border or the 
actin ring created by the fibrillar actin cytoskeleton of the osteoclast. When the 
osteoclasts are actively resorbing, they form podosomes, which attach to bone 
matrix, rather than focal adhesions as formed by most cells. Podosomes are 
composed of an actin core surrounded by αvβ3 integrins and associated 
cytoskeletal proteins (Clarke, 2008). 
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Osteocytes represent terminally differentiated osteoblasts and function within 
syncytial networks to support bone structure and metabolism. In the adult 
skeleton, osteocytes account for 90–95% of all bone cells, compared to 4–6% 
osteoblasts and approximately 1–2% osteoclasts (Clarke, 2008; Clifford et al, 
2013). Once the matrix is mineralized, some osteoblasts remain trapped within 
vacuoles called lacunae, becoming transformed into osteocytes. Osteocytes 
maintain connection with each other and cells on the bone surface through 
dendritic processes generally radiating towards the bone surface and the blood 
supply. The dendritic processes travel through the bone in tiny canals called 
canaliculi while the cell body is encased in lacunae. This interconnection allows 
osteocytes to function as a network of sensory cells that respond to mechanical 
loading through this extensive network (Fernandez et al, 2006; Clarke, 2008; 
Clifford et al, 2013). Osteocytes are linked metabolically and electrically through 
gap junctions composed primarily of connexin 43 (Plotkin et al, 2002). Connexins 
are integral cellular proteins that maintain gap junctions between cells to allow 
direct communication through intercellular channels. Gap junctions are required 
for osteocyte maturation, activity, and survival (Clarke, 2008).Osteocytes have 
long been thought to control biologic activity of bone since they transduce stress 
signals from bending or stretching of bone into bone resorption or formation 
(Fernandez et al, 2006; Clarke, 2008; Buck and Dumanian, 2011; Clifford et al, 
2013). Signaling mechanisms involved in mechanotransduction include 
prostaglandin E2, cyclo-oxygenase 2, various kinases, Runx2, and nitrous oxide 
(Clarke, 2008). It has also been shown that osteocytes have another important 
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function: to regulate phosphate homeostasis; therefore, the osteocyte network 
may also function as an endocrine gland (Clifford et al, 2013). Until recently, the 
markers described for osteocytes were limited to low- or no-alkaline 
phosphatase, high casein kinase II, high osteocalcin protein expression, and high 
CD44 as compared to osteoblasts. At the present time, osteocyte markers such 
as E11/gp38, phosphate-regulating neutral endopeptidase on the chromosome X 
(Phex), dentin matrix protein 1 (DMP1), sclerostin, FGF23, and ORP150 are well 
known (Clifford et al, 2013) (Table 2) 
 
 
Marker Expression Function 
E11/gp38 
CD44 
Early embedding cell 
More highly expressed in 
osteocytes compared to 
osteoblasts 
Dendrite formation 
Hyaluronic acid receptor 
associated with E11 and 
linked to cytoskeleton 
Fimbrin All osteocytes Dendritic branching 
Phex Early and late osteocytes Phosphate metabolism 
OF45/MEPE Late osteoblasts through 
osteocytes 
Inhibitor of bone 
formation/regulator of 
phosphate metabolism 
DMP1 Early and mature 
osteocytes 
Phosphate metabolism 
and mineralization 
Sclerostin Late embedded 
osteocyte 
Inhibitor of bone 
formation 
FGF23 Early and mature 
osteocytes 
Induces 
hypophosphatemia 
ORP150 Mature osteocytes Protection from hypoxia 
 
 
 
 
Table 2 Osteocyte markers  
Adapted from Clifford et al, 2013 
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1.2.3 Bone matrix 
Bone matrix represents 90% of the composition of the bone volume. It consists of 
four major components: inorganic or mineral matrix (65%), organix matrix (20%), 
and lipids and water (< 15%) (Clarke, 2008). 
Organic matrix, secreted by osteoblasts, is predominantly type I collagen (90%) 
(Table 3) with trace amounts of types III and V and FACIT collagens at certain 
stages of bone formation that may help define collagen fibril diameter. FACIT 
collagens are members of the family of Fibril-Associated Collagens with 
Interrupted Triple Helices, a group of non-fibrillar collagens that serve as 
molecular bridges that are important for the organization and stability of 
extracellular matrices. The presence of small amounts of collagen type III has 
been found, related to Sharpey’s fibers. It is believed that collagen has no great 
affinity for calcium, for this reason other proteins are involved in mineral 
deposition (Fernandez et al, 2006; Clarke, 2008; Buck and Dumanian, 2011). 
Osteoblasts also synthesize and secrete non-collagenous proteins which make 
up 10 to 15% of total bone protein. The non-collagenous proteins are divided 
broadly into several categories, including serum-derived proteins, proteoglycans, 
glycosylated proteins, SIBLINGs (Small Integrin-Binding Ligands N-Glycosylated 
proteins), gla-containing proteins, and growth factors (Fernandez et al, 2006; 
Clarke, 2008; Clifford et al, 2013). 
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(i) Serum-derived proteins include, mainly, albumin and α₂-HS-
glycoprotein. These proteins have good affinity for hydroxyapatite, and 
therefore are able to bind to bone matrix. 
(ii) Proteoglycans are large molecules and make up 10% on the non-
collagenous proteins, and bone matrix contains several members of 
this family such as versican (chondroitin-sulphate), hyaluronan 
(glycosaminoglycan), decorin, biglycan, perlecan, osteoadherin, 
lumican, aspirin, and fibromodulin among others. 
(iii) Glycosylated proteins with various functions are abundant in bone. 
During bone formation, it is distinctive the synthesis of high levels of 
alkaline phosphatase, thus it is considered a good marker of osteoblast 
activity. This enzyme liberates inorganic phosphate from phosphoric 
esters, and is necessary for mineralization. The most abundant non-
collagenous protein produced by bone cells is osteonectin, and it plays 
a role in the regulation of cellular adhesion between the matrix and the 
cells as well as is important for normal bone mineralization. 
(iv) Bone cells produce at least 12 proteins that may mediate cell 
attachment. Among them, they are five proteins that are 
phosphorylated and/or sulfated, and contain the RGD tripeptide (Arg-
Gly-Asn), also called SIBLINGs: osteopontin, bone sialoprotein, dentin 
matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP), and 
matrix extracellular phosphoprotein (MEPE). These glycoproteins are 
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essential to bone regeneration and remodeling processes because the 
Arg-Gly-Asn sequence is recognized by osteoblast and osteoclast 
integrins. They also act as bone cell surface receptors, allowing the 
adhesion of the cells to the extracellular matrix, and activating signals. 
Other proteins that participate in cell attachment are fibronectin, 
vitronectin, fibrillin and thrombospondins. 
(v) Four bone matrix non-collagenous proteins can be distinguished in the 
group of Gla-containing proteins: matrix gla protein (MGP), 
osteocalcin, periostin, and protein S. Osteocalcin is a matrix protein 
produced by osteoblasts and platelets. In human bone, osteocalcin is 
concentrated in osteocytes, and its release may be a signal in the bone 
turnover cascade. Its measurements in serum have proved valuable as 
a marker of bone turnover in metabolic disease states. 
(vi) Growth factors include the bone morphogenetic proteins, transforming 
growth factors β family, interleukin-1, and interleikn-6, for example. 
These factors all play important roles in bone osteogenesis, 
mineralization, and remodeling (Table 3). 
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Table 3 Osteoid matrix 
proteins marker 
Adapted from Clifford et al, 2013. Primer on the metabolic bone diseases and disorders of 
mineral metabolism. 
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The inorganic bone matrix accounts for 99% of the body's storage of calcium, 
85% of the phosphorous, and 40-60% of the magnesium and sodium stores. 
Inorganic matrix is mainly in the form of hydroxyapatite and provides the majority 
of bone strength, stiffness, and resistance to compressive forces. Removal of the 
inorganic matrix makes bone soft, malleable, and spongy (Buck, 2011). The 
extracellular mineralized matrix is now considered as something more than 
simply a reservoir of calcium and phosphorous, since it constitutes a reserve of 
proteins that participate in the regulation of cellular differentiation and in the 
integrity and function of bone tissue (Young, 2003). 
 
1.2.4 Bone growth, modeling, and remodeling 
Bone growth occurs longitudinally and radially by the process of endochondral 
ossification and appositional bone growth, respectively. Longitudinal growth 
occurs at the growth plates, where cartilage proliferates in the epiphyseal and 
metaphyseal areas of long bones, before subsequently undergoing 
mineralization to form primary new bone. Appositional bone growth arises at the 
level of the periosteum, with subsequent resorption of old bone at the level of the 
endosteum (Clarke, 2008; Buck, 2011). 
By the process of modeling, the bones change their shape in response to 
physiologic influences or mechanical forces. Modeling of the cranium, for 
example, is thought to be transmitted via mechano-transduction signals from 
underlying brain growth (Stool and Vig, 2003). Bones may enlarge or change 
axis by subtraction or addition of bone to the appropriate surfaces by 
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independent action of osteoblasts and osteoclasts in response to biomechanical 
forces. Bones normally widen with age in response to periosteal apposition of 
new bone and endosteal resorption of old bone (Clarke, 2008). Wolff’s law states 
that bones change shape to accommodate stresses placed upon them 
(Sommerfeldt and Rubin, 2001). In fact, bone resorption occurs if stress does not 
happen and is reinforced where stress forces are applied. An example is the 
resorption of an edentuolous mandible from the lack of the normal forces of 
mastication (Buck, 2011). 
Bone remodeling is the process that takes place to maintain bone health and 
strength as well as mineral homeostasis. The remodeling process resorbs old 
bone and forms new bone to prevent accumulation of bone micro-damage 
(Clarke, 2008; Buck, 2011). The bone remodeling unit is composed of a tightly 
coupled group of osteoclasts and osteoblasts that sequentially carry out 
resorption of old bone and formation of new bone. The remodeling cycle is 
composed of four sequential phases; activation, that includes fusion of multiple 
mononuclear cells to form multinucleated preosteoclasts; resorption, mediated by 
osteoclasts and takes only approximately 2 to 4 weeks during each remodeling 
cycle; reversal, where preosteoblasts are recruited to begin new bone formation, 
and formation that takes approximately 4 to 6 months to be completed. 
Osteoblasts synthesize new collagenous organic matrix and regulate 
mineralization of matrix by releasing small, membrane-bound matrix vesicles that 
concentrate calcium and phosphate and enzymatically destroy mineralization 
inhibitors such as pyrophosphate or proteoglycans (Anderson, 2003). 
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Remodeling begins at birth and continues through adulthood to the time of death 
(Clarke, 2008; Buck, 2011). 
 
1.3 Mesenchymal stem cells (MSCs) 
 
1.3.1 History 
Although the early work of Tavassoli and Crosby (Tavassoli and Crosby, 1968) 
clearly set up proof of an inherent osteogenic potential associated with bone 
marrow (BM), the specific identity of any cell functioning as a progenitor of 
differentiated bone cells could not be outlined. Few years later, Friedenstein et al 
(Friedenstein, 1970), in a series of studies, verified that the ability of bone 
marrow cells of generating new bone marrow when transplanted into a different 
site, was associated with a secondary subpopulation of BM cells. These cells 
were distinct from the majority of hematopoietic cells by their rapid adherence to 
tissue culture vessels and by the fibroblast-like appearance of their progeny in 
culture, indicating their origin from the stromal compartment of BM (Bianco et al, 
2008). These investigators also demonstrated that seeding of BM cell 
suspensions at clonal density resulted in the establishment of discrete colonies 
initiated by single cells. These colonies represented the colony-forming unit 
fibroblastic (CFU-F). Additional study reviews by Friedenstein (Friedenstein, 
1990) of in vivo transplantations, led to the conclusion that the progeny a single 
BM stromal cell could generate multiple skeletal tissues (bone, cartilage, adipose 
tissue, and fibrous tissue). Friedenstein and Owen called this cell a BM stromal 
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stem cell (Owen and Friedenstein, 1988). Consequently, these initial studies 
revealed that a second type of stem cell could be present in the BM and, 
specifically, in the hematopoiesis-supporting stroma. In 1999, Pittenger et al 
(Pittenger et al, 1999)  published an additional similar work and the concept of a 
non-hematopoietic stem cell in BM start being repeated worldwide. The term 
mesenchymal stem cell, proposed previously by Caplan in 1991 (Caplan, 1991) 
as an alternative to stromal or osteogenic stem cell, earned wide acceptance. 
 
1.3.2 Biological characteristics of MSCs 
Stem cells are defined as clonogenic, undifferentiated cells characterized by their 
ability to self-renew and give rise to terminally differentiated cells of multiple 
lineages (Shanti et al, 2007; Deng et al, 2008; Eckfeldt et al, 2005). Stem cells 
have been isolated and characterized from embryonic, fetal, and adult tissues 
(Shanti et al, 2007). Due to ethical, political and technical issues, the use of 
embryonic and fetal stem cells is still controversial, so using adult or postnatal 
stem cells has become more accepted (Shanti, RM et al, 2007; Deng et al, 2008; 
Keller, 2005). A variety of tissues can serve as source for the different type of 
adult stem cells (Ratajczak et al, 2014; Sousa et al, 2014; Shanti et al, 2007) 
(Table 4). 
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The term mesenchymal stem cell is based on the premise that the cells can 
differentiate into a variety of mesodermal tissues including bone, cartilage, and 
adipose (Si, YL et al, 2011). In line with this concept, an important feature of 
MSCs is their ability to differentiate into several mesenchymal lineages such as 
osteoblasts, chondrocytes, adipocytes, myoblasts, and tenocytes (Pittenger et al, 
1999; Deng et al, 2008; Pittenger, 2008). There is also evidence that MSCs could 
have the potential to differentiate into cells of ectodermal lineage such as 
neurons, as well as endodermal lineage such as hepatocytes (Jiang et al, 2002; 
Lee et al, 2004; Tomita et al, 2007). Moreover, an increasing number of evidence 
suggests that MSCs have immunomodulatory properties, anti-inflammatory 
Table 4                                 ADULT STEMM CELLS 
24 
 
effects, and secrete various growth factors and cytokines (Si, YL et al, 2011; 
Shanti et al, 2007; Pittenger, 2008; Chamberlain et al, 2007). The underlying 
mechanisms responsible for the immunosuppressive and anti-inflammatory 
effects of MSCs are not completely understood yet (Si et al, 2011; Shanti et al, 
2007). Nonetheless, evidence states that MSCs lack immunogenicity based on 
their immune phenotype. They express low levels of major histocompatibility 
complex-I (MHC-I), do not express MHC-II or costimulatory molecules that 
include CD40, CD80, and CD86 (Le Blanc and Ringden, 2007; Tse et al, 2003). 
Consequently, MSCs will not activate allogeneic or xenogeneic lymphocytes (Si 
et al, 2011). In addition, MSCs are able to suppress the activation and 
proliferation of both T and B lymphocytes (Jones et al, 2007; Corcione et al, 
2006). MSCs secrete growth factors and cytokines which exhibit autocrine and 
paracrine activities (Pittenger, 2008) that may modulate inflammation, apoptosis, 
fibrosis of damaged tissues and tissue regeneration (Si et al, 2011). Some of 
these include vascular endothelial growth factor (VEGF), stem cell factor (SCF-
1), macrophage colony stimulating factor (M-CSF) and interleukins (IL-1, -6, -7, -
8, -11, -14, and -15), stromal cell-derived factor (SDF-1) (Haynesworth et al, 
1996; Reese et al, 1999; Pittenger, 2008). There are still no uniformly accepted 
markers to confirm homogeneity of MSCs (Si et al, 2011; Shanti et al, 2007; 
Chamberlain et al, 2007; Chen and Tuan, 2008). For this reason, the 
International Society for Cell Therapy has issued the minimal set of standard 
criteria to identify MSCs (Dominici et al, 2006). These include: (i) the ability to 
adhere to plastic surfaces under standard culture conditions; (ii) positive 
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expression of CD73, CD90, and CD105; (iii) lack of expression of CD14, CD19, 
CD 31, CD34, CD45, and human leucocyte antigen-DR (HLA-DR) surface 
molecules; (iv) multipotent ability to differentiate into bone, cartilage, and adipose 
tissue; and (v) immunomodulatory functions. 
In addition to the bone marrow, MSCs are also found in almost all postnatal 
organs and tissues, including periosteum, adipose tissue, periodontal ligament, 
dermis, deciduous teeth, vascular pericytes, trabecular bone, umbilical cord and 
umbilical cord blood as well as amniotic membrane (Bianco, 2008; Rebelatto et 
al, 2008; Seo et al, 2004; Miura et al, 2003; Markov et al, 2007; Brighton et al, 
1992; Mageed et al, 2007; Alviano et al, 2007; Si et al, 2011). Bone marrow, 
adipose tissue, umbilical cord blood, and umbilical cord are usually considered 
as the main sources of MSCs for tissue regeneration and engineering (Si et al, 
2011). Apart from being the first documented source of MSCs, bone marrow has 
proven to be reproducible and convenient site in all species for harvesting MSCs. 
(Si et al, 2011; Pittenger, 2008). While MSCs from different tissues display 
similar basic biological features, there are considerable disparities among them 
such as difference in the expansion potential under identical culture conditions 
(Kern et al, 2006), and age-related functional properties. Furthermore, the 
existence of site-specific variation in bone cell responses has been suggested in 
the literature. Diverse studies have proposed that MSCs derived from craniofacial 
and axial/appendicular bones are phenotypically and functionally distinctive 
based on their different embryological origins (Akintoye et al, 2006; Gronthos et 
al, 2006). The jaw bones arise embryologically from neural crest cells of the 
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neuroectoderm germ layer, while the axial and appendicular bones arise from the 
mesoderm (Akintoye et al, 2006; Aghaloo et al, 2010; Chai and Maxson, 2006). 
In addition, the mandible and maxilla, are formed by intra membranous 
ossification and, in the case of the mandible, secondary cartilage at its proximal 
end contributes endochondral components at later stages of development. 
Meckel's cartilage participates, to a limited extent, in the formation of the 
mandible, but two secondary cartilages (coronoid and condylar) contribute also to 
the mandible (Clifford et al, 2013). Furthermore, the jaw bone could develop non-
odontogenic bone pathologies such as osteoclast-like giant cells and fibrous 
lesions found in cherubism (Ueki et al, 2001) and hyperparathyroid jaw tumor 
syndrome that do not occur in non-oral bones (Simonds et al, 2002). Additionally, 
osteonecrosis of the jaws caused by bone antiresorptives such as 
bisphosphonates and denosumab (Ruggiero et al, 2004) affect only the maxilla 
and mandible, suggesting different homeostatic mechanisms between the jaws 
and long bones. In an earlier study on skeletal site-dependent responsiveness of 
bone cells, Malpe et al (Malpe et al, 1997) assessed their responsiveness to 
insulin-like growth factors (IGFs), which are important regulators of bone 
metabolism. They concluded that there are skeletal site-dependent differences in 
the production of IGF system components and suggest that the regulation of 
bone metabolism may vary at various skeletal sites. 
Akintoye et al (Akintoye et al, 2006) investigated skeletal site-specific phenotypic 
and functional differences between orofacial (maxilla and mandible) and axial 
(iliac crest) human BMSCs in same individuals in vitro and in vivo. The results 
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suggested that orofacial BMSCs are unique cell populations, and that the 
differences between both types of cells are skeletal site-dependent, possibly 
related to distinctive embryological origins and adjustment to functional demands 
at each skeletal site.  
Aghaloo et al (Aghaloo et al, 2010) hypothesized that rat mandible vs. long-bone 
marrow-derived cells possess different osteogenic potential. By using bone 
marrow stromal cells derived from rat mandible and from rat tibiae, these 
investigators compared the in vitro osteoblastic differentiation and in vivo bone 
formation capacity of both cell types. They reported that there is an amplified 
osteogenic potential and augmented capacity of mandibular BMSCs to induce 
bone formation in vitro and in vivo. 
 
1.3.3 Clinical applications of MSCs 
MSCs are viable cell populations for tissue engineering, regenerative medicine, 
and autoimmune disease therapy because of their multipotent capacity, ease of 
culture expansion and low immunogenicity (Chamberlain et al, 2007; Meirelles et 
al, 2008; Si et al, 2011). 
a)  MSCs in cardiovascular conditions 
Some studies have demonstrated that MSCs could have an important function in 
myocardial infarctions and ischemic cardiomyopathies (Psaltis et al, 2008; 
Ohnishi et al, 2007). This therapeutic capacity could be completed by different 
functions such as direct differentiation into cardiac tissue (Gojo et al, 2003); 
secretion of cytokines and growth factors (Kinnaird et al, 2004); through 
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immunosuppressive properties that might decrease inflammation of damaged 
myocardial tissue (Du et al, 2008); and through stimulation of endogenous repair 
(Paul et al, 2009). In the study by Gojo et al  (Gojo et al, 2003), it was 
demonstrated that the injection of adult MSCs into healthy adult myocardium 
could produce cardiomyocytes, endothelial cells, and pericytes or smooth muscle 
cells, revealing that cultured MSCs have the capacity to engraft into healthy 
tissue and can differentiate into several cell types in vivo. 
a)  MSCs in diabetes 
Therapeutic efficacy of MSCs in diabetes mellitus has been mentioned in some 
reports. In the study by Chao et al (Chao et al, 2008), for example, MSCs from 
Wharton’s jelly of the human umbilical cord were successfully differentiated into 
mature islet-like cell clusters with the ability of producing insulin in vitro and in 
vivo. Working with mice, Ezquer et al (Ezquer et al, 2008) demonstrated that the 
systemic administration of bone marrow-derived MSCs could control 
hyperglycemia and prevents renal damage in type I diabetes. Nonetheless, the 
mechanisms by the MSCs could have this therapeutic effect is still unclear. Some 
authors (Xie et al, 2009) have proposed that MSCs differentiate directly into 
functionally competent new β-cells. 
b)  MSCs in neurological disorders 
According to some studies, MSCs could have neuroprotective effects in central 
nervous system injuries and progressive degenerative diseases. This role has 
been described for spinal cord injuries (Himes et al, 2006); Parkinson’s disease 
(Park et al, 2008); autoimmune encephalomyelitis (Zhang et al, 2006), and 
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multiple system atrophy (Lee and Park, 2009), among others. Interestingly, it is 
unrevealed if MSCs could differentiate into neural cells in vivo. Blandini et al 
(Blandini et al, 2010) showed that human MSCs in vitro expressed some neural 
markers including nestin, β III tubulin and  microtubule-associated protein 2 
(MAP-2), but did not express a glial or specific neuronal markers. However, after 
these cells were transplanted into rats, they lost positivity for nestin and 
expressed a glial-like phenotype. Hofstetter et al (Hofstetter et al, 2002) found 
that rat MSCs injected into rats with spinal cord injuries, formed guiding strands 
in the injured spinal cord facilitating regeneration. 
c)  MSCs in graft-versus-host disease (GVHD) 
As a result of the immunomodulatory properties of MSCs, infusions of this cell 
type have been used to treat GVHD developed in patients with allogeneic 
hematopoietic stem cell transplantations (Si et al, 2011). Le Blanc et al (Le Blanc 
et al, 2004) transplanted haploidentical mesenchymal stem cells in a patient who 
had progressive severe GVHD that was unresponsive to all types of therapy. 
They reported remarkable decrease of symptoms in this patient. Later, in a 
multicenter, phase II experimental study, Le Blanc et al (Le Blanc et al, 2008) 
treated 55 patients with steroid-resistant, severe, acute GVHD with mesenchymal 
stem cells. More than 50% of the patients had a complete response and nine 
showed improvement. 
d)  MSCs in bone/cartilage defects 
Degenerative bone diseases such as osteoarthritis (OA), rheumatoid arthritis 
(RA), and osteogenesis imperfecta (OI) have found great treatment options in 
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MSCs. Properties of MSCs such as the ease of isolation and expansion and the 
multipotential differentiation capacity, especially the chondrogenic differentiation 
property of MSCs, make MSCs the cell type of choice for articular cartilage tissue 
engineering that intends to replace and regenerate the diseased structure in joint 
diseases. Moreover, their potent immunosuppressive and anti-inflammatory 
functions can be harnessed for therapeutic application in degenerative joint 
diseases mentioned above (Chen and Tuan, 2008). Cartilage tissue engineering 
has used the chondrogenic differentiation potential of MSCs loaded on a three 
dimensional (3-D) scaffold as replacement tissue for cartilage repair (Chen and 
Tuan, 2008). In addition, MSCs have been used directly in cell therapy for in situ 
repair of OA cartilage. The study performed by Murphy et al (Murphy et al, 2003), 
treated induced OA in goats with autologous MSCs in hyaluronan solution. Their 
results demonstrated inefficient engraftment of MSCs to articular cartilage. They 
concluded that the favorable effect of MSCs, on cartilage protection and on OA 
progression, was probably due to induction of endogenous progenitor cells.  
These cells were responsible to regenerate meniscus that, in turn, retarded 
cartilage degeneration associated with OA.  This study, and others (Augello et al, 
2007; Noth et al, 2008), have suggested that MSC-based graft exert a 
therapeutic effect in arthritis, possibly through their trophic effect and their anti-
inflammatory and immunosuppressive actions, which can significantly affect the 
local environment and resident endogenous tissue progenitor cells in carrying out 
the regenerative function (Chen and Tuan, 2008). A T-cell-mediated systemic 
disease like RA is characterized by articular cartilage damage (Si et al, 2011), 
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and the potential therapeutic value of MSCs in its treatment has been evaluated 
in some studies. Zheng et al (Zheng et al, 2008) showed that bone marrow-
derived MSCs and MSC-differentiated chondrocytes could suppress type II 
collagen-reactive T-cell responses in RA. This suggests that MSCs could be a 
potential candidate for RA treatment in future if this is further confirmed in vivo. 
Horwitz et al (Horwitz et al, 2002) demonstrated the viability of bone marrow-
derived mesenchymal cells therapy in a group of six children with severe OI. 
They infused allogeneic cells and five patients showed engraftment in one or 
more sites, including bone, skin, and marrow stroma, and had an acceleration of 
growth velocity during the first 6 months post-infusion. Despite the outcomes of 
all studies mentioned above, caution should be exercised as this field of research 
is still developing and conflicting results have been reported in different systems 
from different labs (Chen and Tuan, 2008; Si et al, 2011). 
e) Applications in maxillofacial surgery 
MSCs have shown to be an ideal cell source for maxillofacial tissue engineering. 
When these cells are used with scaffolding materials that possess suitable 
biological and physical properties, tissue regeneration from cell-based therapies 
can produce desirable clinical outcomes (Shanti et al, 2007). MSCs have been 
also used to deliver genes or gene products such as bone morphogenetic 
proteins for bone repair (Chang et al, 2003) or the use of bone marrow-derived 
MSCs as vehicles for chemotherapeutics (e.g. Interferon-β) into tumors (Studeny 
et al, 2002). A number of delivery vehicles loaded with MSCs have been 
employed to heal critical-sized segmental bone defects. An example of this is the 
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study by Bruder et al (Bruder et al, 1998) who examined the effect of cultured 
autologous MSCs on the healing of critical-sized segmental defects in the femora 
of adult female dogs. The cells were loaded onto porous ceramic of 
hydroxyapatite and beta-tricalcium phosphate ceramic. It was found a greater 
amount of bone in the implants that had been loaded with mesenchymal stem 
cells compared with the implants that had not been loaded with cells. In pediatric 
patients, cell-based tissue engineering, preferably using autologous cells, 
presents a promising, alternative method for skull bone reconstruction (Shanti et 
al, 2007). A 7-year-old girl with widespread calvarial defects after severe head 
injury was successfully treated with autologous adipose-derived stem cells that 
were grafted to the calvarial defects (Lendeckel et al, 2004). The stem cells were 
kept in place using autologous fibrin glue. Mechanical fixation was attained by 
two large, resorbable macroporous sheets acting as a soft tissue barrier at the 
same time. After 3 months, postoperative computed tomography scans showed 
new bone formation and near complete calvarial continuity. Certainly, more 
advances in the engineering of craniofacial bone are necessary, as well as 
development of resorbable scaffolds that will replicate tissue shape and form 
while degrading in a controlled manner (Shanti et al, 2007). Another maxillofacial 
use of MSCs is in temporomandibular joint (TMJ) reconstruction. As the TMJ is 
susceptible to diverse degenerative pathologies, cell-based tissue engineering 
approaches using MSCs for the replacement of mandibular condyles offer an 
important therapeutic option (Shanti et al, 2007). In the literature some reports 
(Alhadlaq et al, 2003; Tuli et al, 2004) have described different approaches for 
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the ex vivo development of articular tissue component, such as mandibular 
condyle. However, a significant amount of research is still needed before tissue-
engineered mandibular condyles can be placed for clinical uses (Shanti et al, 
2007). 
 
1.3.4 Isolation of MSCs 
MSCs can be obtained from multiple tissues but bone marrow offers the most 
readily available source. Most of the information about MSCs, specifically 
biological properties and characteristics, is from bone marrow-derived cells 
(Shanti et al, 2007). In vitro MSCs expansion is necessary for regenerative and 
immunotherapeutic approaches since adult bone marrow contains low 
percentage of MSCs and a significant number of cells is required for the 
specialized therapies (Sotiropoulou et al , 2006). Effective isolation and 
expansion of MSCs depends on several factors such as culture medium, starting 
and passaging cell-plating density, culture surfaces, addition of supplementary 
factors, and the effects of donor age and cryopreservation (Colter et al, 2000; 
Sekiya et al, 2002; Caterson et al, 2002; Pittenger, 2008; Sotiropoulou et al , 
2006). Many different formulations of growth media have been used in 
experimental and clinical protocols to isolate and growth MSCs (Pittenger, 2008; 
Sotiropoulou et al, 2006).  
Numerous methods have been proposed for qualitative assessment of MSCs 
isolated for clinical use varying from simple colony-forming assays to more 
34 
 
complex morphological characterizations. To mention some of these approaches, 
in the study by DiGirolamo et al (DiGirolamo et al, 1999) the replicative potential 
of human marrow stromal cells was evaluated by a simple colony-forming assay 
in which samples from early passages were plated at low densities of about 10 
cells per cm2. On the other hand, Smith et al (Smith et al, 2004) proposed a more 
sophisticated morphological analysis that may be useful as a rapid method to 
characterize small stem-like cells from a number of adult tissues. Sotiropoulou et 
al (Sotiropoulou et al, 2006) investigated the optimal culture conditions for 
isolation and expansion of human MSCs. Among several growth media, they 
concluded that those based on α-Minimum Essential Medium (α-MEM) are more 
suitable for both isolation and expansion of multipotent MSCs. In cell culture 
processes, the addition of L-glutamine to the medium has been considered a 
problem, as reported in some studies. This compound is susceptible to both 
chemical and metabolic deamination, producing ammonia which can be inhibitory 
to cell growth. Therefore, glutamine-containing dipeptides such as alanyl-
glutamine and glycyl-glutamine have been considered as potential substitutes for 
glutamine in culture medium due to their stability (Christie and Buttler, 1994; 
Sotiropoulou et al, 2006). The other major component of MSCs isolation and 
growth media is fetal bovine serum (FBS). Most media preparations usually use 
10% fetal calf serum to provide a mixture of undefined growth factors, cytokines, 
and attachment factors.   FBS contains, particularly, platelet-derived growth 
factor (PDGF), basic fibroblast growth factor (b-FGF or FGF-2), and epidermal 
growth factor (EGF) as well as small amounts of other growth factors. It has been 
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established that serum-free defined media lack attachment factors to aid MSC 
attachment and cell yields tend to be low (Pittenger, 2008). Regarding passaging 
cell-plating density, Sotiropoulou et al (Sotiropoulou et al, 2006) found that initial 
plating densities of 5,000 to 10,000 cells/cm2 resulted in much higher numbers of 
the starting MSC-enriched adherent population. These results are consistent with 
previous reports that have evaluated parameters for MSCs expansion and 
displayed that plating MSCs at low density benefits proliferation and stemness 
preservation (Sekiya et al, 2002; Colter et al, 2001; Prockop et al, 2001). 
Sotiropoulou et al (Sotiropoulou et al, 2006) also stated that an additional factor 
that influences the expansion of human MSCs is the quality of plastic surface 
used for their adhesion. These investigators used culture flasks from four 
different companies and demonstrated that the quality of cells produced did not 
differ among the different types of flasks. In addition, this study assessed effect 
of b-FGF concentrations on MSCs proliferative capacities. This study supports 
previous reports (Tsutsumi et al, 2001; Hori et al, 2004) that isolation and 
proliferative potential of MSCs are dose-dependent. 
 
1.3.5 MSCs model organisms 
MSCs have important applications not only in human regenerative medicine but 
also in veterinary medicine. Animal models are widely used to study the 
properties and potential of stem cells providing valuable information for future 
applications in human medicine (Ribitsch et al, 2010). Currently, the focus of 
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attention in veterinary medicine and research is the use of MSCs from either 
extra embryonic or adult tissues. 
Most of the conventional MSC research has been performed by using cells 
isolated from humans and murine models. Nonetheless, MSCs have also been 
isolated from unconventional model organisms, such as cat (Felis catus), dog 
(Canis familiaris), chicken (Gallus gallus), duck (Anas platyrhyncha), goat (Capra 
hircus), buffalo (Bubalus bubalis), cattle (Bos taurus), rabbit (Oryctolagus 
cuniculus), pig (Sus scrofa), sheep (Ovis aries), horse (Equus caballus) and 
guinea pig (Cavia porcellus) (Calloni et al, 2014). 
a) Cat (Felis catus) 
Martin et al (Martin et al, 2002) isolated, for the first time, feline MSCs from bone 
marrow. Later, other reports have described isolation of MSCs from adipose 
tissue (Webb et al, 2011), umbilical cord blood (Jin et al, 2008), and fetal fluid 
and membranes (Iacono et al, 2012). Cat MSCs exhibit a morphology similar to 
MSCs isolated from mice and humans, characterized by the expression of classic 
MSC-associated markers (CD9, CD44, CD90 and CD105) and the absence of 
the surface proteins CD14, CD34 and CD45 (Calloni et al, 2014). 
b) Cattle (Bos Taurus) 
Studies have reported isolation of bovine MSCs from bone marrow and umbilical 
cord (Bosnakovski et al, 2005; Mauck et al, 2006). They express the cell surface 
markers CD29, CD73, CD90 and CD105 and present a fibroblast-like 
morphology. Generally, most of these bovine MSCs studies have investigated in 
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vitro culture systems to achieve and analyze chondrogenic differentiation (Calloni 
et al, 2014). 
c) Rabbit (Oryctolagus curriculus) 
Different tissues have served as a source of rabbit MSCs: bone marrow, adipose 
tissue, peripheral blood, synovium, periosteum, placenta and fetal liver (Moreno 
et al, 2010; Hui et al, 2005; Lee et al, 2012). Morphology of the cells resembles 
the classic fibroblast-liike shape and can differentiate in vitro into chondroblasts 
and epithelial-like cells (Li et al, 2012: Wan et al, 2006). Other reports have 
demonstrated in vivo and in vitro differentiation to osteoblasts, adipocytes and 
corneal epithelial cells (Wan et al, 2006; Gu et al, 2009). 
d) Sheep (Ovis aries) 
Ovine MSCs have been isolated from bone marrow, particularly from the iliac 
crest region, adipose tissue, amniotic fluid, dental pulp and periodontal ligament 
(Niemeyer et al, 2010; Martinez-Lorenzo et al, 2009; Shaw et al, 2011). However, 
in 2003 MSCs were isolated for the first time from sheep umbilical cord (Murphy 
et al, 2003). Rentsch et al (Rentsch et al, 2010) reported that ovine MSCs and 
human-derived MSCs have similar proliferative characteristics and differentiated 
into the same lineages. Other studies have reported specifically in vitro and in 
vivo adipogenic and osteogenic differentiation (Niemeyer et al, 2010; Rentsch et 
al, 2010). 
 
 
 
38 
 
1.4 Canine mesenchymal stem cells (cMSCs) 
 
1.4.1 Why characterize cMSCs? 
To optimize clinical applications of stem cells, it is paramount to test safety and 
efficacy in large-animal models of preclinical studies. Canine models are known 
to accurately predict clinical outcomes in adult stem cell transplantation and are, 
therefore, likely to act as accurate preclinical models for stem cell therapies. In 
fact, long-term outcomes of organ or hematopoietic transplantation in dogs have 
accurately predicted outcomes in humans (Csaki et al, 2007; Hayes et al, 2008; 
Volk et al, 2012) 
Using dogs as dependable preclinical models in the development of cellular 
transplantation therapies has important advantages over some other laboratory 
animals. Canines experience external and environmental elements that are 
associated with different pathologies such as cancer, obesity, and traumatic 
injuries. Also the clinical presentation and progression of these diseases are 
similar to their equivalents in humans (Parker et al, 2010; Volk et al, 2012). 
Distinctive treatment options, imaging, and repeated biological sampling are, 
especially, possible in dogs due to their size and availability of vital veterinary 
infrastructure. These circumstances plus continuing clinical progresses in 
companion animal care have increased sensitivity to detect adverse side effects 
of new therapies that would otherwise reduce risks to humans (Volk et al, 2012). 
Clearly, canine model has a significant value for translational studies that can 
advance human medicine and also enhance veterinary therapies.  For further 
39 
 
advancements of cMSC-based regenerative medicine and tissue engineering, it 
is essential to gain more insight into their differentiation capacity, define donor 
characteristics, refine ex vivo expansion strategies, and evaluate the tissues 
formed by these cells at the biochemical, ultrastructural and 
immunomorphological levels. 
 
1.4.2 What is known about cMSCs? 
Canine mesenchymal stem cells (cMSCs) can be obtained from numerous 
sources such as bone marrow, adipose tissue, umbilical cord blood, umbilical 
cord matrix, umbilical cord vein, periodontal ligament, dental pulp, amniotic fluid, 
and amniotic membrane (Vieira et al, 2010; Reich et al, 2012; Volk et al, 2005; 
Volk et al, 2012; Dissanayaka et al, 2011; Wang et al, 2012; Seo et al, 2009; 
Zucconi et al, 2010; Uranio et al, 2011; Kisiel et al, 2012). The greatest volume of 
the studies on cMSCs has been performed using cells from bone marrow and 
adipose tissue. The procedure for obtaining bone marrow in dogs is usually easy 
and relatively non-invasive. Commonly used donor sites are the proximal 
humerus, proximal femur or the tuber coxae (Crovace et al, 2008; Fortier and 
Travis, 2011). Adipose tissue is also considered an attractive source for MSCs, 
mainly, due to the accessibility of the tissue at various sites in the body (Stewart 
& Stewart, 2011), and ability to collect it during routine canine surgery or 
liposuction techniques (Vieira et al, 2010). Depending on the source from which 
the cells are isolated, canine MSCs can be passaged around 6 to 11 times 
(Martinello et al, 2011). In the literature, there are various reports that have 
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reported about characterization of cMSCs based on their morphology, 
immunophenotype, and gene expression (Table 5).  
 
 
Morphologically the cMSCs display the typical fibroblast-like shape, but with 
some variations such as elongated and cuboidal outlines (Csaki et al, 2007; De 
Schauwer et al, 2011). Depending on the source of the cells, several studies 
have showed that cMSCs have a variable surface marker profile. These reports 
showed positive and simultaneous expression of several markers such as CD29, 
Table 5 
Adapted from de Bakker et al, 2014. Veterinary Quarterly, 2014 
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CD44, CD90, and MHC-I, while being negative for CD34, CD45, CD14, CD105, 
and MHC-II, among others (Table 5). 
Mathieu et al (Mathieu et al, 2009) emphasized the importance of using specific 
anti-canine antibodies in cell surface marker characterization due to the lack of 
cross-reactivity between the dog cell surface markers and human antibodies. 
This fact could explain some negative results for classic MSCs markers in canine 
cells. Interestingly, some trials have demonstrated that cMSCs secrete various 
cytokines that allow them to inhibit leucocyte proliferation. Kang et al (Kang et al, 
2008) demonstrated that canine adipose-derived MSCs expressed soluble 
factors such as transforming growth factor beta, IL-6, IL-8, vascular endothelial 
growth factor, hepatocyte growth factor, and others. These factors were 
associated with immunomodulatory effects of the cMSCs. As human MSCs, 
cMSCs also express pluripotency-associated transcription factors NanoG, Oct4, 
and Sox2 (Table 5). 
Generally, one important characteristic of MSCs is their osteogenic, 
chondrogenic, and adipogenic potential (Pittenger et al, 1999). This 
differentiation capacity has also been demonstrated in cMSCs isolated from bone 
marrow and adipose tissue. In addition, some authors have investigated cMSCs 
harvested from other anatomical parts such as amniotic membrane, umbilical 
cord blood, Wharton’s jelly, muscle, periosteum (Csaki et al, 2007; Neupane et 
al, 2008; Vieira et al, 2010; Volk et al, 2012; Kisiel et al, 2012; Park et al, 2012; 
Kang et al, 2012; Guercio et al, 2013) 
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Volk et al (Volk et al, 2012) studied canine bone marrow-derived MSCs obtained 
from humerus, femur, tibia, an iliac crest and the effects of donor characteristics 
(age and harvest site) and ex vivo expansion on the differentiation potential of 
the cells. Osteogenesis, chondrogenesis, and adipogenesis were, particularly, 
evaluated. The authors found that advancing age had a negative effect on 
colony-forming unit-fibroblastic as well as osteogenic potential. Site of harvest 
was also found to have substantial effects on MSC properties. 
Csaki et al (Csaki et al, 2007) verified the in vitro multilineage differentiation 
potential of isolated adult canine bone marrow MSCs from femur, at the 
ultrastructural and immunomorphological levels. They demonstrated that the cells 
had proliferative capacities and, under appropriate culture conditions could 
differentiate well into functional osteoblasts, adipocytes and chondrocytes during 
in vitro development. 
Park et al (Park et al, 2012) isolated and characterized MSCs from six different 
canine amniotic membrane tissues. They demonstrated that the amniotic 
membrane-derived MSCs proliferated actively, showed adherence to plastic 
culture surface and their morphology was similar to those typical MSCs with a 
spindle, fibroblast-like shape. Additionally, the cells displayed multipotent 
differentiation capacity of osteogenesis, adipogenesis, neurogenesis, and 
chondrogenesis in vitro. 
Kisiel et al (Kisiel et al, 2012) firstly, isolated and characterized canine muscle-
derived MSCs and periosteum-derived MSCs. Secondly; they compared the 
proliferation potential of MSCs from these two potential donor sites with two 
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conventional canine sources; bone marrow and adipose tissue. These 
investigators were able to demonstrate that plastic-adherent cells, with the 
distinctive fibroblastic phenotype, were isolated and expanded from all four donor 
tissues. Furthermore, the cells expressed surface markers CD90 and CD44, and 
were negative for CD34 and CD45. Positive expression of pluripotency-
associated transcription factors Sox2, Oct4, and NANOG was also noticed. In 
terms of differentiation ability, muscle-derived MSCs appeared to have the 
greatest adipogenic potential compared with the other tissue-derived MSCs. 
Osteogenic differentiation was achieved in all four MSC types demonstrated by 
the expression of alkaline phosphatase, Runx2, osterix, and osteopontin, 
however the study does not indicate the tissue that exhibited higher or lower 
expression of these bone markers. 
The authors reported that their attempts at differentiating canine MSCs into the 
chondrogenic lineage were unsuccessful based on morphological and 
histochemical assessments. Periosteum was a superior tissue source in 
providing the greatest number of MSCs per gram of tissue when the cells were 
grown to 80% to 100% confluence in passage 1, suggesting that periosteum 
derived cMSCs may be useful in allogeneic applications. 
Osteogenic differentiation has been demonstrated by morphological changes of 
the cells under induction, which have adopted polygonal appearance containing 
nodular aggregates that stained positively with von Kossa. Ultrastructural cellular 
changes, translated into a bigger number of cell organelles, and a well-organized 
extracellular matrix have been observed through transmission electron 
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microscopy. Additionally, cultures grown under osteogenic conditions have 
deposited a mineralized matrix that has stained with Alzarin red S. To 
complement mineralization assays, mRNA levels or protein expression of 
osteogenic markers such as Runx2, collagen type I, bone sialoprotein, 
osteonectin, osterix, osteopontin, and osteocalcin have been assessed (Kadiyala 
et al, 1997; Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Volk et al, 
2012). 
Adipogenic differentiation has been confirmed by the presence of round- shape 
cells with cytoplasmic lipid vacuoles stained with Oil Red O technique. Under 
electron microscopy the newly formed adipocytes have confirmed the 
accumulation of lipid droplets in their cytoplasm with well-developed rough 
endoplasmic reticulum and mitochondria. Characterization of the adipogenic 
extracellular matrix by immune-electron microscopy has revealed abundant 
amounts of collagen type I and adiponectin, the most abundant protein in 
adipose tissue. Based on real-time PCR and Western blotting, cells under 
adipogenesis induction have displayed significant amounts of adiponectin, 
upregulation of the adipocyte-specific transcription factor peroxisome 
proliferative-activated receptor γ (PPARγ), lipoprotein lipase (LPL), fatty acid 
binding protein-4 (FABP4), and β1-integrin. PPARγ is important for adipocyte 
differentiation and stabilizing the metabolic function of differentiated adipocytes 
(Lazar et al, 2002; Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Volk 
et al, 2012) 
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Chondrogenic differentiation has been characterized by the accumulation of 
glycosaminoglycans (GAG) evidenced by Alcian blue staining in the differentiated 
cMSCs. Analysis through transmission electron microscopy has shown newly 
formed chondrocytes with round shape, and containing high amounts of 
glycogen, numerous cell organelles, and augmented quantities of euchromatin in 
nuclei. Immuno-transmission electron microscopy has disclosed that newly 
formed extracellular matrix contained abundant amount of collagen type II and 
cartilage specific proteoglycans (CSPG). Western blot analysis of whole cell 
extracts have confirmed high amounts of collagen type II, CSPG, and activation 
of the cartilage specific transcription factor sex-determining region Y box 9 
(Sox9) (Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Volk et al, 
2012). 
As illustrated above, osteogenic, adipogenic, and chondrogenic differentiation 
have been mostly reported for cMSCs. Nonetheless, the potentials of these cells 
to differentiate into other lineages such as myogenic (Vieira et al, 2010; 
Martinello et al, 2011) or neurogenic lines (Kamishina et al, 2006; Seo et al, 
2009; Park et al, 2012; Oda et al, 2013)  have also been documented. 
Vieira et al (Vieira et al, 2010) reported isolation, characterization, and 
multilineage differentiation potential of canine adipose-derived MSCs, obtained 
from subcutaneous adipose tissue by liposuction and biopsy procedures. 
Besides demonstrating the cMSCs were able to differentiate into adipogenic, 
chondrogenic, and osteogenic cells, they also showed differentiation ability into 
myogenic lineage. After 10 days in myogenic medium, adipose-derived MSCs 
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formed multinucleated structures. Myogenic differentiation was confirmed by the 
expression of myosin measured through immunofluorescence, and gene 
expression levels of myogenin, dystrophin, and MyoD only in induced cells. 
Oda et al (Oda et al, 2013) used three previously reported methods to 
differentiate cMSCs, harvested from iliac crest, into neuron-like cells. Then, the 
cells were characterized according to morphological analysis and expression of 
neuronal markers. cMSCs under neurogenic induction experienced sequential 
changes in their appearance, from fibroblastic to neuron-like cells with multiple 
branching processes. Immunocytochemical analysis showed that the induced 
cells expressed markers of both immature neurons (nestin, 84.7%) and mature 
neuronal cells (microtubule-associated protein-2 (MAP2), 95.7%; βIII-tubulin 
protein, 12.9%; glial fibrillary acidic protein (GFAP), 9.2%). The investigators 
concluded that, under appropriate in vitro conditions, canine bone marrow-
derived MSCs can be efficiently differentiated into cells with neuronal 
phenotypes. 
In the study by Park et al (Park et al, 2012), neurogenesis differentiation was 
evaluated using amniotic membrane-derived canine MSCs. The authors 
measured the expression of the neural-associated markers GFAP, βIII-tubulin, 
and MAP2 by immunostaining and real-time PCR. Induced cMSCs expressed 
GFAP assessed at both protein and gene levels and in non-induced cells. The 
specific neural markers βIII-tubulin and MAP2 were expressed in cells cultured 
under neural differentiation conditions. 
 
47 
 
1.4.3 What is unknown about cMSCs? 
Full understanding of cMSCs biology is yet to be conclusively elucidated. More 
detailed knowledge of differentiation and manipulation of cMSCs into other 
tissues are crucial to their application for MSC-based therapies in veterinary 
medicine, and indirectly in human MSC-based therapies. 
Few studies have been published targeting certain factors that may have 
significant effects on differentiation capacity and culture expansion of cMSCs. 
Precise definition of optimal donor age may have significant impact when 
decisions have to be made on choice of autologous or allogeneic MSC therapies. 
If autologous cells are to be used for clinical trials in older individuals, it is very 
important to determine if the age of the donor will influence the outcomes of the 
therapy (Volk et al, 2012). MSC-based therapies require a significant number of 
cells; therefore, the knowledge of ex vivo cell expansion, and associated 
variables should be completely clarified. Volk et al (Volk et al, 2012) studied the 
influence of cell passage on the osteogenic capacity of cMSCs, and found that 
this diminishes with increasing passage. The authors suggested that the 
shortening of MSC telomere length may explain this diminished differentiation 
capacity. Beside culture expansion, it is important to also assess post-expansion 
cell yield per gram of donor tissue and specific characteristics of induction media 
used for cMSCs culture (Volk et al, 2012; Kisiel et al, 2012; de Bakkler et al, 
2014).  
As previously stated, a number of studies have reported isolation and in vitro 
differentiation capacity of cMSCS, but not many trials have followed up to identify 
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their cell surface markers and mRNA expression profiles. Furthermore, the 
mechanisms by which cMSCs act to repair individual tissues in vivo are still 
unclear. More preclinical or clinical studies are necessary to define if the cMSCs 
function through direct differentiation into specific tissue lines, immunomodulatory 
action and secretion of growth factors, or both. 
Skeletal site-specific properties of cMSCs from the same subject and their site-
dependent effects on tissue regeneration have not been clearly defined. Previous 
studies focusing on bone marrow-derived as well as adipose-derived cMSCs 
suggest that MSC frequency and differentiation capacity may also be influenced 
by the specific site of tissue harvest, but these studies have compared response 
of MSCs from long bones, with the absence, to our knowledge, of trials making 
comparisons between cells from the orofacial region and axial/appendicular 
skeleton ((Csaki et al, 2007; Neupane et al, 2008; Vieira et al, 2010; Kisiel et al, 
2012; Volk et al, 2012). 
Although many of the tendon/ligament injuries present in humans are also 
frequently diagnosed in dogs (de Bakker et al, 2013), regenerative MSC-based 
therapies for this kind of lesions, either traumatic or degenerative, have not been 
completely investigated in canine medicine (de Bakker et al, 2014). 
 
1.4.4 Therapeutic applications of cMSCs 
The use of MSCs as an alternative treatment option for several canine diseases 
such as spinal cord injuries, bone defects/ degenerative diseases, cardiovascular 
pathologies, metabolic diseases, and others has been reported in the literature.  
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Trials on healing of spinal cord injury have found cMSCs to be sustainable 
therapies. Jung et al (Jung et al, 2009) determined the efficacy of autologous and 
allogeneic bone marrow-derived MSC transplantation in experimentally-induced 
spinal cord injury of dogs. By using three groups of 10 beagle dogs, they injected 
autologous MSCs to the first group, allogeneic MSCs to the second, and no 
MSCs to the third one. They observed that both autologous and allogeneic 
groups showed an improvement in the neurological signs of pelvic limbs 
compared with the control group. These findings were corroborated with 
magnetic resonance imaging, histopathological examinations, and 
immunofluorescence analysis. It was concluded that autologous and allogeneic 
MSCs transplantation can be clinically helpful therapies for spinal cord injuries. 
Lim et al (Lim et al, 2007) used adult mongrel dogs to evaluate the effects of 
allogeneic umbilical cord blood (UCB)-derived MSCs and recombinant methionyl 
human granulocyte colony-stimulating factor (rmhGCSF) on spinal cord injuries 
performed using balloon compression methods at the first lumbar vertebra. One 
week after the induction of the neuronal lesions, UCB-MSCs were directly 
injected into the injured site of the spinal cord and rmhGCSF was administered 
subcutaneously. The dogs were divided in 5 groups: no treatment, saline 
treatment, UCB-MSCs, rmhGCSF, and UCB-MSCs plus rmhGCSF (UCBG). The 
results were evaluated after 2, 4, and 8 weeks after transplantation. The 
investigators found no significant differences between the UCB-MSC and UCBG 
groups, and between the no treatment and saline groups. In addition, there was 
no evidence of regeneration of spinal cord tissue by magnetic resonance imaging 
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and histology, but significant evidence of functional and sensory improvement 
after allogeneic UCB-MSCs transplantation was observed. Moreover, they 
noticed newly formed neuronal tissues in the injured structures of the spinal cord 
in the UCB-MSC and UCBG groups. In summary, they determined that the 
outcomes of this study showed that transplantation of UCB-MSCs resulted in 
recovered nerve function in dogs after a spinal cord injury. 
Treatment of bone defects in dogs have been described in the literature based, 
mainly, on associations of cMSCs and different scaffolds. Sun et al (Sun et al, 
2011) harvested and cultured bone marrow-derived MSCs from the iliac crest of 
beagle dogs. The cells were pre-osteodifferentiated and seeded into a 
chitosan/collagen I/β-glycerophosphate (β-GP) composite hydrogel to promote 
osteogenesis. After 28 days, scanning electronic microscopy observations 
indicated good spreading of bone marrow MSCs and mineral nodules were 
observed in this hydrogel scaffold. The in vivo phase consisted in subcutaneous 
injection of the chitosan/collagen/β-GP hydrogel loaded with pre-
osteodifferentiated dog-bone marrow MSCs into nude mouse dorsum. After 4 
weeks, partial bone formation was detected in the hydrogel which indicated that 
chitosan/collagen/β-GP hydrogel composite could induce osteodifferentiation in 
cMSCs without exposure to a continual supply of external osteogenic factors. In 
conclusion, the authors stated that this hydrogel composite should be useful as a 
bone regeneration scaffold. Yoshioka et al (Yoshioka et al, 2012) created 
bilateral bone defect in the upper incisor regions of beagle dogs, and evaluated 
bone regeneration achieved by transplantation of cMSCs derived from iliac bone 
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marrow mixed with carbonated hydroxyapatite (CAP) particles. Six months after 
the transplantation, absolute closure of the jaw cleft was attained on the 
experimental side. Occlusal X-ray and histological examinations revealed that the 
regenerated bone on the experimental side was almost equivalent to the original 
bone contiguous to the jaw cleft. The researchers suggested that the application 
of MSCs with CAP particles can become a new treatment modality for bone 
regeneration for patients with congenital anomalies in the orofacial region such 
as cleft lip and palate. 
The role of cMSCs in regeneration of muscular tissues, particularly 
cardiomyocytes, and therefore in heart diseases has also been studied. Some 
breeds of dogs, particularly the Cavalier King Charles Spaniel, are affected by 
cardiac diseases such as endocardiosis or dilated cardiomyopathy that contribute 
to more than 50% of mortalities in these dogs (Bonnett et al., 2005; Hodgkiss-
Geere et al, 2012). Studies like the one performed by Hodgkiss-Geere et al 
(Hodgkiss-Geere et al, 2012) suggests that cMSCs-based therapy might provide 
benefits to these heart pathologies. These investigators analyzed adult canine 
cardiac stem cells taken from canine cardiac tissue, specifically from the right/ 
left atria and ventricles immediately post-mortem. They were able to isolate, 
characterize, and explore the cells ability to differentiate into cardiac myocytes. 
The cells were exposed to four differentiation protocols and demonstrated the 
following marker profile: stem cell marker c-kit and early cardiac differentiation 
markers GATA 4 and flk-1, positive; the cardiomyocyte marker cardiac troponin T 
and another early cardiac differentiation marker, NKx2.5, low. Gene expression 
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studies demonstrated that cardiac directed differentiation was partially achieved, 
with up-regulation of cardiac troponin T and NKx2.5, and down-regulation of c-kit 
and endothelial lineage markers. However the cells did not express the 
ryanodine receptor or β1-adrenergic receptors and did not contract 
spontaneously. Based on these results, the authors concluded that the canine 
heart has a reliable and reproducible resident population of adult stem cells, and 
that, even though, complete differentiation was not achieved and key 
components of the contractile machinery were not detected, the study could 
achieve a comprehensive characterization of canine cardiac stem cells and 
serves as a foundation for further studies about optimizing conditions needed for 
cardiac differentiation. In an earlier study, Silva et al (Silva et al, 2005) showed 
that, in a canine chronic myocardial ischemia model, the intramyocardial 
injections of bone marrow-derived MSCs resulted in differentiation of those cells 
into smooth muscle and endothelial cells that translated to increased vascularity 
and improved cardiac function. In conclusion, they suggested that, with further 
investigation, the MSC transplantation might become an alternative therapy for 
ischemic heart failure.  
The combination of genetic engineering and cell transplantation provides a novel 
promise for diabetes treatment. Some reports in the literature have investigated 
these optional therapies using cMSCs. In a diabetes study, by Zhu et al (Zhu et 
al, 2011), bone-derived Beagle canine mesenchymal stem cells were isolated, 
expanded, and transfected with a recombinant retroviral plasmid containing 
human insulin and enhanced green fluorescent protein (EGFP). Then the cells 
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were transplanted into the livers of diabetic Beagle dogs by arterial intervention 
technique. EGFP was used as the radiotracer to detect the insulin secretion, the 
colonization of bone marrow derived-MSCs (BMSCs), and the long-term effects 
of BMSCs on experimental animals. The variations of body weight, blood 
glucose, serum insulin levels, and plasma C-peptide were determined after 
autotransplantation. An increase in the body weight, a decrease in blood glucose 
levels, and a reduction in the need for insulin injections were reported, but no β-
pancreatic cell regeneration was observed. As a general conclusion, the authors 
expressed that experimental diabetes could be relieved effectively by intrahepatic 
autotransplantation of BMSCs expressing human insulin, which implies a new 
strategy of gene therapy for type I diabetes. 
Continuing preclinical and clinical trials are necessary in canine medicine. Dogs 
are considered to be a superior animal model for humans; therefore, advanced 
state-of-art research in this field will benefit both dogs and humans.  
 
2 RESEARCH AIMS 
2.1 Purpose 
Investigation of mesenchymal stem cell-based therapies such as bone tissue 
engineering procedures and regenerative medicine has gained increasing 
importance in both human and veterinary medicine. There are many properties of 
mesenchymal stem cells (MSCs) that make their use an attractive option for 
clinical applications. The body of studies on MSCs has focused on cells isolated 
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from humans and murine models. Among other organisms, dogs are recognized 
to be a suitable model for MSC studies due to their anatomical, biochemical, 
physiological, and pathophysiological characteristics. Increasing veterinary 
clinical trials involving canine subjects will provide unique more opportunities to 
assess both the efficacy and safety of adult stem cell therapies that can be 
translated to human medicine. Nevertheless, detailed knowledge of biology of 
canine MSCs (cMSCs) has not been completely elucidated.  The effect of many 
factors such as anatomical site, passage number, culturing protocols, and donor 
characteristics of cells from canine origin still remain unclear. Further 
understanding of cMSC biology will provide valuable information to refine cell-
based therapies such as donor graft selection for bone regeneration in veterinary 
as well as human medicine. 
The main purpose of this study was to characterize cMSCs isolated from beagle 
dogs based on proliferative and multipotent differentiation properties.  
 
2.2 Specific aims 
This study intends to characterize cMSCs through the following specific 
objectives; 
1) To evaluate in vitro expansion and proliferative potential of cryopreserved 
cMSCs from two different anatomical sites: orofacial region (mandible) and 
appendicular bone (femur). 
2) To investigate and compare in vitro differentiation potential of cMSCs into 
distinct cellular lineages, namely osteogenic, adipogenic, chondrogenic, 
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and neurogenic, from two different anatomical sites: orofacial region 
(mandible) and appendicular bone (femur). 
3) To demonstrate and compare in vivo osteogenic differentiation of cMSCs 
from two different anatomical sites: orofacial region (mandible) and 
appendicular bone (femur). 
4) To test whether mandible-cMSCs (M-CMSCs) demonstrate superior 
proliferative and multipotent differentiation properties than femur-cMSCs 
(F-cMSCs) from same animals. 
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3 MATERIAL AND METHODS 
3.1 Experiment outline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram method 
EXPERIMENT OUTLINE 
M-cMSCs F-cMSCs 
PROLIFERATION/SURVIVAL 
 Colony Forming 
Efficiency 
 Population doubling 
DIFFERENTIATION 
OSTEOGENESIS (in vitro and in vivo) 
 Alkaline phosphatase 
 Bone sialoprotein 
 Osteocalcin 
 Osteopontin 
 In vivo transplantation 
ADIPOGENESIS 
 Oil Red O staining 
CHONDROGENESIS 
 Alcian blue staining 
NEUROGENESIS 
 Immunostaining 
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3.2 Sample and cell culture 
Canine MSCs from the mandibular body and proximal femur of 2 Beagle dogs  
(ages: 3 weeks, 2 females) were previously isolated and cryopreserved in Dr. 
Akintoye’s laboratory.  
The primary cMSCs were further expanded in culture using growth medium 
consisting of α-MEM supplemented with 10% fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA), 100 U/ml Penicillin, 100 mg/ml streptomycin 
sulfate and 2 mM glutamine (Gibco, Life technologies, NY)  and maintained at 
370C, in humidified atmosphere of 5% CO2 and air. Non-adherent cells were 
washed away, after 24 hours, with phosphate-buffered saline (PBS) and the 
medium was changed every 3-4 days. At 80% of confluence, the cMSCs were 
detached with 0.5% trypsin (Invitrogen-Life Technologies, Carlsberg CA  and split 
as detailed in experiments outlined below. Overall, the cells used in this study 
were within passage 6 or lower. 
 
3.3 Cell proliferation 
The proliferation rate of cMSCs was assessed by growth curve analysis 
(Akintoye et al, 2006). Cells were plated at 9.5 x 103 cells/cm2 in 6-well plates 
(Coming Life Sciences, Acton, MA) in α-MEM growth medium, which was 
changed twice weekly. Cells were released on days 1, 3, 6, 9, 12, and 15 and 
counted using hemocytometer to plot a growth curve. 
 
 
58 
 
3.4 Colony forming efficiency (CFE) assay 
Colony forming efficiency assay was performed as previously described 
(Akintoye et al, 2006; Volk et al, 2012). Primary cMSCs were cultured in triplicate 
25 cm² plastic culture flasks at 10¹, 10² and 10³ cells/flask with non-osteogenic 
growth medium. Cells were fixed on day 14 with 100% methanol, subsequently 
stained with methyl violet (Sigma-Aldrich, St Louis, MO) and aggregates of 50 or 
more cells were counted as colonies. 
 
3.5 Life span measurements 
Long term survival of cMSCs was assessed by population doublings (PD) as 
previously described (Akintoye et al, 2006). Cells were plated at 1 x 10⁶ 
cells/flask, and PD was calculated from generation number after repeated cell 
passage at 1:10 split ratio until the cells attained replicate senescence. 
 
3.6 Canine telomerase activity assay 
The presence of canine telomerase reverse transcriptase (cTERT) was 
determined by Western blotting of nuclear extracts isolated with Nuclei EZ Prep 
Isolation Kit according to the manufacturer’s protocol (Sigma-Aldrich). Nuclear 
extracts were obtained at different passages during the population doubling 
experiment above. Culture dishes were washed with Dulbecco’s Phosphate 
Buffered Saline and the cells were harvested by using Nuclei EZ lysis buffer. The 
entire cell lysates were centrifuged at 3000 rpm, and the clear supernatant was 
aspirated, conserving the nuclei pellet on ice. The supernatant contains 
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cytoplasmic components and was saved for later analysis. Nuclei pellets were 
resuspended in Nuclei lysis buffer, and centrifuged again. After this, the nuclei 
pellets were resuspended in Nuclei EZ storage and frozen at -80 °C to be used in 
the next steps. Equal amounts of nuclear extracts were used to evaluate 
expression levels of monoclonal antibody to cTERT. The blots were probed with 
rabbit polyclonal telomerase reverse transcriptase antibody (Novus Biologicals) 
at 1:1000.This primary antibody was followed by anti-rabbit (1:2000) as 
secondary antibody. Probing of blots with anti β-actin (1:2000) served as loading 
control. Immunoreactive bands were analyzed digitally with Kodak Image Station 
4000MM. 
 
3.7 In vitro osteogenic differentiation 
Osteogenic differentiation was performed as previously described (Volk et al, 
2005; Volk et al, 2012). Canine MSCs were cultured at 1 x 104 cells/cm2 in 10 
sixty mm dishes (Corning Life Sciences, Acton, MA) with α-MEM growth medium 
without osteogenic inducers until they reached confluence. Half of the dishes 
(n=5 dishes) were pre-coated with poly-L-lysine (Sigma-Aldrich) to enhance cell 
attachment under long-term culture. At confluence, the cells in coated dishes 
were exposed to osteogenic medium containing supplements of 100 ng/ml of 
human bone morphogenetic protein-2 (BMP-2, GenScript, Piscataway, NJ, USA) 
and 100 µM L-Ascorbic acid 2-phosphate (10−4 M) for 7 and 14 days. Medium 
was changed twice weekly. Cells in the other set of dishes (n=5) were cultured in 
α-MEM growth medium without inducers and used as control. At 7 and 14 days 
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protein lysate and RNA were collected in parallel experimental culture dishes. 
Total protein amount from lysates was determined using the Bicinchoninic acid 
protein assay (Pierce™ BCA Protein Assay Kit). Equal (50 μg) protein amount 
was loaded on a 4 – 20% gradient gel and transferred on nitrocellulose 
membrane for western blotting. The membranes were probed with the following 
primary antibodies: rabbit anti-bone sialoprotein (BSP) polyclonal antibody (Bioss 
Inc.) at 1:200; rabbit anti-osteocalcin (OCN) polyclonal antibody (Bioss Inc.) at 
1:200; rabbit anti-osteopontin (OPN) antibody (Rockland Inc.) at 1:500, and 
rabbit anti-alkaline phosphatase (ALP) antibody (Novus Biologicals) at 1:800. 
Primary anti β-actin (1:1000) and anti-α-tubulin (1:200) served as loading 
controls. Furthermore, the primary antibodies were reacted with anti-mouse or 
anti-rabbit secondary antibodies at concentrations ranging from 1:1000 – 1:3000. 
Digital analysis of immunoreactive bands was performed using with Kodak Image 
Station 4000MM (Molecular Imaging Systems, Carestream Health, Rochester, 
NY). 
 
3.8 Isolation of RNA and Real-Time Quantitative Reverse Transcription-
Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from osteogenenically-induced and control cells using 
TRI Reagent® (Sigma-Aldrich). First strand cDNA was prepared with first strand 
SuperScript™ Double-Stranded cDNA Synthesis Kit (Invitrogen Life 
Technologies, Carlsbad, CA) using an oligo-dT primer. Two microliters of first 
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strand cDNA was added to a total volume of 50 μl PCR buffer containing: 1.5 mM 
MgCl2, 200 μM dNTP, 2.5 U Taq DNA polymerase (Promega, Madison, WI) and 
200 nM of each primer set. Real-time PCR was performed with 7300 Fast Real-
Time PCR system (Applied Biosystems, Foster City, CA) using the STBR Green 
Master Mix (Applied Biosystems, Foster City CA) and the following custom-
designed primers:  
Canine BSP - forward 5’-TTGCTCAGCATTTTGGGAATGG-3’; 
Canine BSP – reverse 5’-AACGTGGCCGATACTTAAAGACC-3’; 
Canine Osteocalcin – forward 5’-CTG GTCCAGCAGATGCAAAG-3’;  
Canine Osteocalcin – reverse 5’-CCGCTTGGACACGAAGGTT-3’; 
Canine ALP - forward 5’-TTCAAACCGAGACACAAGCAC T-3’;  
Canine ALP – reverse 5’-GGGTCAGTCACGTTGTTCCTGT-3’; 
Canine Osteopontin - forward  5’-CGAGTCTGATGAATCCGATGA A-3’; 
Canine Osteopontin – reverse 5’-TTGGGTTGCTGGAATGTCAGT-3’.  
Gene expression levels were normalized to the housekeeping gene:  
Canine β2 microglubulin - forward 5’-TCACGACACCCAGCAGAGAA-3’;  
Canine β2 microglubulin – reverse 5’-GGAACCCTGACACGTAGCAGTT-3’. 
 
3.9 In vivo osteogenesis by transplantation into immunocompromised host 
Bone regenerative capacity of femur and mandible cMSCs was evaluated using 
the mouse model of in vivo bone formation in immunocompromised hosts   as 
described by Akintoye et al (Akintoye et al, 2006).  The animal protocol was 
approved by the University of Pennsylvania Office of Regulatory Affairs.. Non-
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induced and osteogenically induced mandible and femur MSCs were 
transplanted into separate subcutaneous pockets of three different animals as 
follows: 2 × 10⁶ cMSCs were attached to 40 mg spheroidal 
hydroxyapatite/tricalcium phosphate (particle size 0.5–1.0 mm, Zimmer, Warsaw, 
IN) and transplanted into separate subcutaneous pockets aseptically created in 
4-week-old immunocompromised nude female mice (NIH-III NU/NU, Charles 
River Laboratories, Wilmington, MA). Transplants were harvested at 6, 8 and 12 
weeks, fixed in 4% paraformaldehyde for 48 hours, decalcified in 10% EDTA (pH 
8.0) and embedded in paraffin. Five-micrometer sections were deparaffinized, 
stained with hematoxylin/eosin, and semi-quantitative bone formation was 
scored, microscopically, by four blinded independent observers as previously 
described (Akintoye et al, 2006). Bone scores, that were performed by the four 
observers, ranged from 0 (no bone observed within the transplant), 1 (minimal 
amount of bone), 2 (weak bone formation occupying only a small portion of the 
transplant), 3 (moderate bone formation occupying a significant portion but less 
than 50% of the transplant) and 4 (abundant bone formation, occupying more 
than 50% of the transplant). 
 
3.10 Adipogenic differentiation 
Adipogenic differentiation was induced as previously described (Akintoye et al, 
2006; Volk et al, 2012). cMSCs were cultured at 1.8 x 10³ cells/cm2 in 4-well 
chamber slides (Coming Life Sciences, Acton, MA) using α-MEM growth medium 
without adipogenic inducers. At approximately 100% confluence, the growth 
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medium was switched to adipogenic medium containing supplements of 10−8 M 
dexamethasone, insulin (1 μg/ml), 1-methyl-3-isobutylxanthine (IBMX, 5 × 10−8 
M), indomethacin (10−4 M), and fetal bovine serum (FBS) 10% for 15 days; 
medium was changed twice weekly. Similar culture plates without exposure to 
adipogenic medium served as control. At 15 days, the cells were rinsed with 2x 
phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 10 minutes 
at room temperature, stained with 0.3% Oil Red O for 1 hour, and counterstained 
with 1% Fast green dye for 10 minutes. The slides were mounted with coverslip 
and lipid droplets were identified and quantified microscopically. Using Image J, 
lipid droplets were counted for the cell types, femur and mandible, non-induced 
and induced cells, and then the number of droplets per cell was calculated. 
 
3.11 Chondrogenic differentiation 
Chondrogenesis differentiation assay was performed as previously described 
(Csaki et al, 2007; Park et al, 2012; Volk et al, 2012). Chondrogenic 
differentiation was induced using the pellet method. cMSCs were cultured in 75 
cm² flasks at 75 x 10⁴ cells/cm² until they reached 80-90% confluence. Then, the 
cells were trypsinized and counted with hemocytometer. 2 x 10⁶ cells were 
transferred into various 15 ml polypropylene tubes. The cells were centrifuged to 
a pellet form, and supernatant was aspirated without disturbing the pellets. 
Thereafter, the pellets were washed with PBS, then cultured in chondrogenic 
medium consisting of alpha-MEM. supplemented with 10−8 M dexamethasone, 
ITS+ 1%, L-Ascorbic acid 2-phosphate (10−4 M), transforming growth factor-beta 
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3 (TGF-β3) 10ng/ml, β-glycerophosphate 10mM, glutamine 2 mM, penicillin-
streptomycin sulfate 100 U, and pyruvate 2 mM. Cell pellets cultured with growth 
medium without chondrogenic inducers were used as control. Chondrogenic 
medium was replenished every 2-3 days. The pellets were harvested after 4 and 
8 weeks for histological analysis, Pellets were fixed with 4% paraformaldehyde 
for 12 hours, and processed for paraffin embedding. 5 µm sections were, stained 
with Alcian blue solution, counterstained with nuclear fast red solution, 
dehydrated, and mounted with coverslip for histological evaluation.  
 
3.12 Neural differentiation 
Canine MSCs were cultured at 4 x 10³ cells/cm2 in 8-well chamber slides coated 
with collagen (Corning® BioCoat™) with normal α-MEM growth medium without 
inducers until they reached confluence. Thereafter, 4 chambers were exposed to 
neurogenic medium, and the other 4 were kept in normal growth medium as the 
control group. Neurogenically induced cells were pre-incubated for 24 hr. with α-
MEM medium supplemented with 20% fetal bovine serum (Atlanta biological, 
Lawrenceville, GA), 100 U/ml Penicillin, 100 mg/ml streptomycin sulfate, 2 mM 
glutamine (Gibco, Life technologies, NY), and 10 ng/ml β-fibroblast growth factor 
(β-FGF, 10 ng/ml) (BD Biosciences) while control cells were still retained in α-
MEM growth medium without β-FGF. The pre-induction medium was then 
removed, and the cells were washed with PBS and transferred to neuronal 
induction medium composed of: α-MEM supplemented with 20% fetal bovine 
serum, 100 U/ml Penicillin, 100 mg/ml streptomycin sulfate, 2 mM glutamine 
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(Gibco, Life technologies, NY), 2% dimethyl sulfoxide (DMSO; Sigma-Aldrich), 10 
ng/ml fibroblast growth factor (FGF, 10 ng/ml), 200 μM butylated hydroxyanisole 
(BHA; Sigma-Aldrich), 10 µM Forskolin (Sigma), 25 mM KCl, 2 mM Valproic acid 
(Calbiochem), and 5 µg/mL insulin. Cells were incubated for 24 hours, 4, 7, and 
14 days at 37ºC in a humidified 5% carbon dioxide environment. Neural 
differentiation was evaluated using morphological analysis and immunostaining. 
Early neuronal expression was assessed with anti-nestin polyclonal antibody 
(LifeSpan BioSciences, Inc.), while late neuronal expression was assessed with 
anti-beta III tubulin (Bioss). Cells were fixed with 4% paraformaldehyde, 
incubated in 0.1% TritonX-100 for 5 minutes, blocked with 3% goat serum for 30 
minutes, and incubated overnight with primary antibodies: 1:200 dilution of anti-
nestin and 1:200 anti-beta III. After washing, the samples were incubated with 
1:500 dilution of fluorescent-labeled secondary antibody goat anti-rabbit Alexa 
Fluor 555 (Life Technologies). Nuclei were visualized with 1 ųg/ml of Hoeschst 
33342.  Specimens were serially excited and images were captured on the 
microscope. 
 
3.13 Statistical analysis 
All experiments were performed at least three times; each cell type (induced and 
control) were tested in triplicates, and the resulting data was averaged prior to 
subsequent analysis. The results were expressed as mean ± standard deviation. 
Comparison of responses between mandible-cMSCs and femur-cMSCs was 
measured by the paired t-test analysis and values of p<0.05 were considered 
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statistically significant. Cell proliferation was tested by analyzing slopes of linear 
regression lines of mandible and femur cells. A value of p<0.05 was also 
considered statistically significant. 
 
4 RESULTS 
4.1 Cell culture of cMSCs 
The primary F-cMSCs and M-cMSCs expanded in culture displayed 
characteristic polymorphic, fibroblast-like morphology in monolayer culture, as is 
shown by M-cMSCs (Figure 4). Within about 5 to 6 days, the M-cMSCs were 
usually 80-90% confluent, while F-cMSCs were comparatively at 60-70%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
Figure 4: Representative image of M-cMSCs monolayer showing 
characteristic fibroblast-like morphology. 
20x 
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Figure 5 Cell proliferation: the slope representing the number of mandible 
cells  until day 9 was significant different (p = 0.006) compared with that of 
femur cells, demonstrating that M-cMSCs had higher proliferative rate than 
F-cMSCs. After day 9, the proliferative capacity of both cell types started 
decreasing. 
p = 0.006 
4.2 Cell proliferation 
When cMSCs were plated at low densities of 95,115 cells/cm2 and counted at 
days 1, 3, 6, 9, 12, and 15, M-cMSCs displayed significant higher proliferative 
rates until day 9 compared with those of F-cMSCs. A test of slopes demonstrated 
that the differences between both slopes, mandible and femur, were very 
significant (p= 0.006). Additionally, while F-cMSCs proliferation plateaued at day 
9, the M-cMSCs continued to grow exponentially before plateauing by day 12 
(Fig. 5). 
 
 
 
 
 
Figure 5 
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4.3 Colony forming efficiency assay 
Cells isolated from femur and mandible were apparently similar in terms of their 
ability to form colonies, which were visualized and counted after being stained 
with methyl violet (Figure 6). 
 
 
 
 
 
 
 
 
 
Mean colony forming efficiency per 10⁵ nucleated cells was not significantly 
different between F-cMSCs and M-cMSCs (Figure7) 
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Figure 7 Mean colony forming units per 10⁵ nucleated cells was not significantly different 
between F-cMSCs and M-cMSCs.  
Figure 7 
Figure 6 Colonies in plastic flasks A: F-cMSCs B: M-cMSCs. Arrows indicate 
stained cell colonies of both cell types. 
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4.4 Population doubling and telomerase activity 
Life span of cMSCs assessed by population doublings (PDs) capacity 
demonstrated that M-cMSCs were able to survive until passage 12, which relates 
with a total of 77 days after repeated passaging, but F-cMSCs reached 
replicative senescence at passage 6, which occurred 10 days earlier than M-
cMSCs (Fig. 8). Since this experiment was performed in duplicates, a statistic 
analysis was not possible to be performed. However, qualitatively and as 
mentioned above, mandible cells survived more days compared with femur cells.  
 
 
 
 
 
 
 
 
 
 
 
 
To complement lifespan assessment canine telomerase reverse transcriptase 
(cTERT) activity was evaluated by Western blotting of nuclear extracts isolated at 
different passages of the population doubling experiment. The expression of 
cTERT progressively decreased as the cells progressed toward senescence as 
Figure 8 
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Figure 8 Life span: M-cMSCs were able to survive five more passages 
relative to F-cMSCs 
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demonstrated by immunoreactivity and quantitative analysis of the 
immunoreactive bands. (Fig 9A-B) While F-cMSC TERT was quantitatively 
higher at baseline and subsequent passages, the expression was more short-
lived relative to M-cMSCs (Fig. 9B).   
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Figure 9B Expression of canine TERT relative to baseline: the expression of cTERT was 
downregulated as the cells progressed toward senescence. F-cMSCs demonstrated a 
more short-lived expression compared with m-cMSCs.. 
 Passages of F-cMSCs Passages of M-cMSCs 
cTERT 
β-Actin 
P1    P2   P3   P4  
  
293T 
cTERT 
β-Actin 
P1   P2   P3   P4   P5  P6   P7  P8 
 
Figure 9A Immunoreactive bands of canine telomerase obtained through Western blot 
progressively decreased for both, femur and mandible cells with subsequent passages. β-
actin served as loading control and 293T cells as control for expression of cTERT. 
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Figure 10 Alkaline phosphatase expression at 7 and 14 days of osteogenic 
induction: Although at 7 days the difference was not statistically significant, M-
cMSCs demonstrated higher expression levels of ALP at 7 and 14 day time 
points compared with F-cMSCs. 
7 days p= 0.2 
14 days p= 0.004 
4.5 In vitro osteogenesis 
Time-dependent in vitro osteogenic properties of both induced, M-cMSCs and F-
cMSCs showed increased expression levels of early osteogenic markers such as 
alkaline phosphatase (ALP) and bone sialoprotein (BSP) compared with non-
induced cells. These findings are representative of, at least 3 different 
experiments.  Interestingly, induced mandible cells displayed active expression of 
ALP at 7 days of induction, which showed their initial response to osteogenic 
differentiation. In addition, on day 14 mandible cells exhibited a significant up-
regulation of ALP (p= 0.04) compared with femur cells. As expected, both cell 
types showed maximal ALP expression on day 7 (Figure 10).                              
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 7 days 14 days 
  F-cMSCs   M-cMSCs   F-cMSCs    M-cMSCs 
    ALP 
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In relation to BSP expression at 7 and 14 days of osteogenic induction, there was 
a higher time-dependent BSP expression in mandible cells relative to femur cells. 
As with ALP, there was a statistically significant up-regulation (p= 0.05) of BSP in 
mandible cells at day 14 compared with cells from femoral origin (Figure 11). 
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Figure 11 Bone sialoprotein expression at 7 and 14 days of osteogenic 
induction: there was a higher time-dependent BSP expression in M-cMSCs 
relative to F-cMSCs based on 7 and 14 days. 
14 days p= 0.05 
7 days p= 0.07 
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7 days p= 0.34 
14 days p= 0.11 
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Figure 12 Osteopontin expression at 7 and 14 days of osteogenic induction: there 
was not difference in OPN expression at 7 and 14 days between the two types of 
cells. 
While there were no differences in osteopontin (OPN) expression levels between 
the two cell types, osteocalcin (OCN) was not expressed early by F-cMSCs 
compared to M-cMSCs that consistently demonstrated measurable levels of the 
late osteogenic marker OCN at both 7 and 14 days. (Figures 12 and 13). 
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7 days p= 0.004 
14 days p= 0.03 
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Figure 13 Osteocalcin expression at 7 and 14 days of osteogenic induction: while 
there was no early expression of OCN in F-cMSCs, it was significantly upregulated 
in M-cMSCs relative to F-cMSCs at 7 and 14 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6 Reverse transcriptase polymerase chain reaction (RT-PCR) 
Gene transcripts of ALP, BSP, OPN and OCN were also assessed by real-time 
RT-PCR in cMSCs exposed to osteogenic and non-osteogenic conditions. Gene 
expressions of ALP, BSP, and OCN were significantly up-regulated in mandible 
compared with femur cells at 7 and 14 days of induction (p values indicated in 
the respective graphs). These findings were consistent with Western blot results. 
Figure 13 
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Differences between the two cell types were more clearly defined after 14 days of 
osteogenic stimulation based on significantly upregulated expression levels of 
ALP, BSP and OCN in M-cMSCs relative to F-cMSCs. Interestingly, OPN gene 
transcript was only moderately upregulated in M-cMSCs at day 7 (Fig 14 - A, B, 
C, D). 
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Figure 14 Real time PCR; gene expressions of ALP (A) and BSP (B) were significantly 
upregulated in M-cMSCs compared to F-cMSCs at 7 and 14 days of induction. In terms of 
transcription of OCN (C), it was also upregulated in M-cMSCs relative to F-cMSCs at both 
time periods. However,OPN (D) expression moderately increased at 7 days in M-cMSCs 
compared to F-cMSCs. 
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Figure 15 In vivo bone regeneration after 6 weeks transplantation: hematoxylin 
and eosin stained sections of bone formed in vivo by non-induced and 
osteogenically-induced F-cMSCs. Both cell types, non-induced and induced, 
demonstrated bone formation (woven bone) (B= bone; FT; fibrous tissue; HA: 
hidroxyapatite/tricalcium phosphate carrier; Oc; osteocyte). 
 
4.7 In vivo osteogenesis 
Bone forming capacity of cMSCs assessed by in vivo transplantation showed 
microscopically observable bone nodules in hematoxylin/eosin stained sections 
after 6, 8, and 12 weeks (Figures 15-20). Semi-quantitative analysis using an 
established bone scoring system (Akintoye et al, 2006) showed that bone 
formation capacities of M-cMSCs and F-cMSCs were not different between non-
induced and osteogenically-induced cells (Fig 21). 
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Figure 16 In vivo bone regeneration after 6 weeks transplantation: hematoxylin and eosin 
stained sections of bone formed in vivo by non-induced and osteogenically-induced M-
cMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven 
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc; 
osteocyte). 
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Figure 17 In vivo bone regeneration after 8 weeks transplantation: hematoxylin and eosin 
stained sections of bone formed in vivo by non-induced and osteogenically-induced F-
cMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven 
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc; 
osteocyte; HP: hematopoiesis). 
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Figure 18 In vivo bone regeneration after 8 weeks transplantation: hematoxylin and eosin 
stained sections of bone formed in vivo by non-induced and osteogenically-induced M-
cMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven 
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc; 
osteocyte). 
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Figure 19 In vivo bone regeneration after 12 weeks transplantation: hematoxylin and eosin 
stained sections of bone formed in vivo by non-induced and osteogenically-induced F-
cMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven 
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc; 
osteocyte; HP: hematopoiesis;  
Ad: adipose tissue). 
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Figure 20 In vivo bone regeneration after 12 weeks transplantation: hematoxylin and eosin 
stained sections of bone formed in vivo by non-induced and osteogenically-induced M-
cMSCs. Both cell types, non-induced and induced, demonstrated bone formation (woven 
bone) (B= bone; FT; fibrous tissue; HA: hidroxyapatite/tricalcium phosphate carrier; Oc; 
osteocyte). 
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4.8 Adipogenic differentiation 
After 15 days of adipogenic induction, non-induced and induced cMSCs were 
stained with Oil Red O and observed microscopically to assess lipid droplets 
within cytoplasm. Cell cultures treated with adipogenic induction media were 
found to contain greater accumulation of lipid-rich vacuoles within cells compared 
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Figure 21 In vivo bone regeneration: hematoxylin and eosin stained-sections of 
bone formed in vivo by osteogenically-induced cMSCs transplanted in the subcutis 
of immunocompromised nude mice. Both types of cells, mandible and femur and 
non-induced and induced, formed bone independently of the duration of the 
transplants.  
Figure 21 
81 
 
to the untreated control cells. Oil Red O staining for fat revealed that these 
vacuoles contain neutral lipids consistent with adipocyte phenotype. By 
visualization, M-cMSCs showed more numerous lipid clusters and larger in size 
than those of femur cells. This demonstrates that adipogenic differentiation of the 
mandible cells was apparently more efficient (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After counting the lipid droplets for both cell types, the mean of lipid vacuoles per 
cell was higher in cells under adipogenic induction, femur and mandible, relative 
to non-induced cells. Additionally, mandible cells exhibited a significant (p= 
0.007) higher number of lipid droplets compared with femur cells, which is 
consistent with the visualization assessment (Figure 23). 
F-cMSCs M-cMSCs 
C
o
n
tr
o
l 
A
d
ip
o
g
e
n
e
s
is
 
10x 10x 40x 40x 
Figure 22 Adipogenesis: Oil Red O staining revealed cytoplasmic lipid inclusions in 
both cells, F-cMSCS  and M-cMSCs, cultured in the presence of adipogenic 
inducers, as compared to cells cultured under control conditions. More abundant 
lipid droplets were observed in M-cMSCs relative to F-cMSCS. 
Figure 22 
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4.9 Chondrogenic differentiation 
The chondrogenically-induced and non-induced pelleted cMSCs were assessed 
histologically using Alcian Blue staining after 4 and 8 weeks of pellet culture. 
Comparatively, chondrogenically-induced cells displayed significant higher 
number of chondrocyte-like cells per unit area based on pink to red staining 
patterns (Figures 24-25). M-cMSCs were more responsive to chondrogenic 
Figure 23  
Figure 23 Mean lipid droplets per cell: induced cells, femur and mandible displayed 
higher number of lipid droplets per cell. Induced M-cMSCs showed significant 
higher number of lipid vacuoles than F-cMSCs (p= 0.007). 
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Figure 24 Chondrogenesis differentiation F-cMSCs: 
microphotographs showed an increased number of 
chondrocytes stained with alcian blue technique, in cell 
cultures under chondrogenic induction than cells under non-
induced conditions; CD: chondrocyte. 
CD 
induction especially after 4 weeks because the tissue sections showed 
apparently more chondrocytes per unit area (p = 0.009) (Figure 26). 
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Fig. 25 Chondrogenesis differentiation M-cMSCs: 
microphotographs showed an increased number of 
chondrocytes stained with alcian blue technique, in cell 
cultures under chondrogenic induction than cells under non-
induced conditions. In addition, a higher number of 
chondrocytes was observed in M-cMSCs compared to F-
cMSCs; CD: chondrocyte. 
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4.10 Neurogenic differentiation 
After 24 hours, 4, 7, and 14 days of neurogenic induction, the cMSCs were 
immunostained with two neuronal markers; nestin and βIII-tubulin. Neurogenic 
culture medium induced spindle-shaped morphological changes (Figures 27-36) 
as early as 24 hours post-induction. Long-term neural stimulation further induced 
cMSCs to acquire long cytoplasmic processes and neuron-like morphology with 
characteristic dendritic shape (Figures 27-36). The neuronally-induced cells were 
slightly more reactive to both neuronal markers: nestin and βIII tubulin. 
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Fig. 26 Mean of chondrocytes per unit area for F-cMSCs and M-cMSCS: both types of 
cells demonstrated a significant higher number of chondrocytes at 4 and 8 weeks 
under induced conditions relative to non-induced conditions. At 4 weeks, there was a 
significant (p=0.009) higher number of chondrocytes in induced M-cMSCs compared 
to F-cMSCs. 
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Figure 27 Neurogenesis-nestin 24 hours and 4 days induction: after neural induction, 
induced F-cMSCs changed morphologically into a spindle shape. The induced cells 
acquired more long fibroblastic neuronal extensions, mimicking a dendritic shape, than 
control cells. 
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Figure 28 Neurogenesis-nestin 7 and 4 days induction: Induced F-cMSCs continued to 
undergo spindle-shaped morphological changes. There was similar expression of nestin by 
non-induced and induced cells. 
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Immunostaining of non-induced and induced F-cMSCs with no primary antibody 
(anti-nestin) included showed no expression or extreme decreased expression of 
nestin (Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Induced    Control   
F-cMSCs 
20x 
10x 
Figure 29 Negative control of neurogenesis-
nestin in non-induced and induced F-cMSCs: 
immunofluorescence microphotographs 
showing no expression or extreme decreased 
expression   of the primary antibody anti-
nestin.  
Figure 29 
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Figure 30 Neurogenesis-nestin 24 hours and 4 days induction: after neural induction, 
induced M-cMSCs changed morphologically into a spindle shape. The induced cells 
acquired more long fibroblastic neuronal extensions, mimicking a dendritic shape, than 
control cells. 
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Figure 31 Neurogenesis-nestin 7 and 14 days induction: Induced M-cMSCs 
continued to undergo spindle-shaped morphological changes. There was similar 
expression of nestin by non-induced and induced cells.. 
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Fig. 32 Negative control of neurogenesis-nestin in 
non-induced and induced M-cMSCs: 
immunofluorescence microphotographs showing 
no expression or extreme decreased expression   
of the primary antibody anti-nestin.  
Immunostaining of non-induced and induced M-cMSCs with no primary antibody 
(anti-nestin) included showed no expression or extreme decreased expression of 
nestin (Figure 32). 
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Figure 33 F-cMSCs neurogenesis βIII-tubulin 7 and 14 days induction: 
immunofluorescent microphotographs of F-cMSCs stained with primary antibody against 
βIII-tubulin showed that induced cells adopted more neural-like features than control 
cells. However, control and induced cells demonstrated similar expression of βIII-tubulin. 
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Figure 34 Negative control of neurogenesis- βIII-tubulin in non-induced and induced F-
cMSCs: immunofluorescence microphotographs showing no expression or extreme 
decreased expression   of the primary 
 antibody anti-βIII-tubulin.  
 
Immunostaining of non-induced and induced F-cMSCs with no primary antibody 
(anti- βIII-tubulin) included showed no expression or extreme decreased 
expression of βIII-tubulin (Figure 34). 
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Figure 35 M-cMSCs neurogenesis βIII-tubulin 7 and 14 days induction: 
immunofluorescent microphotographs of M-cMSCs stained with primary antibody against 
βIII-tubulin showed that induced cells adopted more neural-like features than control 
cells. However, control and induced cells demonstrated similar expression of βIII-tubulin. 
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Figure 36 Negative control of neurogenesis- βIII-tubulin in non-induced and induced 
M-cMSCs: immunofluorescence microphotographs showing no expression or 
extreme decreased expression of the  
primary antibody anti-βIII-tubulin.  
 
 
Immunostaining of non-induced and induced M-cMSCs with no primary antibody 
(anti- βIII-tubulin) included showed no expression or extreme decreased 
expression of βIII-tubulin (Figure 36). 
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5 DISCUSSION 
Safety and efficacy of new MSC-based therapies for humans must be assessed 
using two animal species: rodents, usually as first group, and a non-rodent large 
animal as second group (de Bakker et al, 2014). As stated, MSCs can be 
isolated from unconventional model organisms such as dogs, cats, goats, 
rabbits, cattle, sheep, horses, guinea pigs (Calloni et al, 2014). Based on their 
anatomical, pathological, biochemical and physical characteristics, dogs (Canis 
familiaris) are recognized to be reliable and attractive models to assess MSC-
based regenerative medicine and tissue engineering. These advancements 
result in great benefits for translational studies in human medicine, as well as the 
obvious impact on cutting edge veterinary therapies (de Bakker et al, 2014; Volk 
et al, 2012). However, with respect to canine medicine and MSC-based 
therapies, there are still many unknown factors. For example, studies on ideal 
number of cells in transplantation and skeletal site-specific characterization of 
canine stem cells from the orofacial region and axial/appendicular bones have 
not been addressed yet. 
In vitro and in vivo trials with cMSCs have used different tissues and anatomic 
regions as donor sites: adipose tissue (Kisiel et al, 2012; Vieira et al, 2010; 
Martinello et al, 2011; Neupane et al, 2008; Reich et al, 2012; Requicha et al, 
2012), umbilical cord tissue (Seo et al, 2009), umbilical cord blood (Seo et al, 
2009), bone marrow (Csaki et al, 2007; Kisiel et al, 2012, Volk et al, 2012, Volk et 
al, 2005, Eslaminejad and Taghiyar, 2010, Mathieu et al, 2009, Tharasanit et al, 
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2011), dental pulp (Dissanayaka et al, 2011), periodontal; ligament (Wang et al, 
2012), amniotic fluid (Uranio et al, 2011,), muscle (Kisiel et al, 2012),  and 
periosteum (Kisiel et al, 2012). Isolation and characterization of cMSCs from 
bone marrow have used donor sites such as long bones but rarely orofacial 
region. Moreover, studies have focused their attention on the osteogenic 
potential of cMSCs in vitro and in vivo (Kadiyala et al, 1997, Kang et al, 2012, 
Guercio et al, 2012).  
Assessing site-specific differences in cMSCs is of interest, since there are no 
studies comparing, for instance, differentiation capacity of cMSCs between 
orofacial region and appendicular/axial bones. Two studies have found a 
significant increase in osteogenic response from bone marrow-derived human 
MSCs from the orofacial region compared to those harvested from the iliac crest 
(Akintoye et al, 2006; Osyczka et al, 2009). Our study tested a similar hypothesis 
that cMSCs are skeletally site-specific.  In support of previous studies (Csaki et 
al, 2007, Kisiel et al, 2012, Volk et al, 2012); our results demonstrated that 
cMSCs, that were previously collected and cryopreserved, were successfully 
expanded in culture flasks. The cells were able to adhere to plastic surfaces, 
grew uniformly on monolayers and adopted a fibroblastic-like morphology. These 
properties, plus their multi-lineage differentiation capacity exhibited through the 
expression of some osteogenic markers and morphological observations, are in 
accordance with the two criteria established by the International Society for 
Cellular Therapy to characterize MSCs from animal sources (Dominici et al, 
2006). Previous studies have determined that cMSCs can be cryopreserved and 
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still maintain their viability and be induced to differentiate along multiple lineages 
(Kraus and Kirker-Head, 2006, Zhu et al, 2013). 
Proliferative capacity of cMSCs 
Mandible cMSCs displayed higher proliferative rates than those of the femur. 
Mean number of mandible cells was consistently higher than femur cells at all-
time points. Similar higher numbers were observed in the population doubling 
experiment for M-cMSCs. The increased proliferative capacities of M-cMSCs 
indicate more self-renewal ability than those of F-cMSCs. Unlike long bones, 
bones originating from the neural crest cells, such as maxilla and mandible, do 
not contain prominent hematopoietic components (McCauley and Somerman, 
2012). This fact could explain the higher proliferation and population doubling of 
M-cMSCs since stromal cells of non-hematopoietic marrow divide more actively 
than hematopoietic cells, which are usually mitotically latent (Bianco et al, 1999). 
Furthermore, F-cMSCs underwent cellular senescence earlier than M-cMSCs. 
Expression of cTERT confirmed our previous findings since this enzyme was 
downregulated in agreement to the increasing cell passages. The use of TERT in 
our study was based on the knowledge that the tissue distribution of telomerase 
activity in dogs is similar to that in humans, where it is basically restrained to 
malignant cells or cells with high proliferative potential such as MSCs, and not 
found in normal somatic tissues (Zavlaris et al, 2009; Argyle and Nasir, 2003). 
The high specificity of the rabbit polyclonal antibody to cTERT that we used has 
been shown to be as high as 92% according to Zavlaris et al (Zavlaris et al, 
2009) using tumor samples Similarly Akintoye et al (Akintoye et al, 2006) has 
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reported higher proliferation rate, population doubling and telomerase expression 
in human orofacial MSCs relative to those of iliac crest in same individuals. The 
higher telomerase expression of M-cMSCs also correlates with similarly higher 
colony forming efficiency (CFE) relative to F-cMSCs. These site-dependent 
differences have also been reported between cMSCs from ilium that displayed 
relatively higher CFE than femur or humerus (Volk et al, 2012). 
Differentiation of cMSCs 
 Diverse differentiation pathways of M-cMSCs and F-cMSCs were assessed 
including osteogenic, adipogenic, chondrogenic and neurogenic lineages.  
In vitro osteogenesis of cMSCs 
The capacity of MSCs to undergo osteogenic differentiation in vitro is well 
established and they externalize markers known to be expressed by bone 
forming osteoblast.  According to Huang et al (Huang et al, 2007) three different 
stages has been observed in the cell growth of osteoprogenitors in vitro (Figure 
37): (i) the first 4 days are characterized by cell proliferation where a DNA peak is 
observed, (ii) from day 5 to day 14, there is an early cell differentiation where the 
main osteoprogenitor cell marker is ALP. After this initial peak of ALP its level 
starts to drop. Also found at an early stage is the expression of BSP, (iii) the third 
stage, which occurs from day 15 to day 28, is distinguished by terminal 
differentiation and matrix maturation. The main markers at this stage are 
osteocalcin and osteopontin, followed by calcium and phosphate deposition. In 
general, ALP rises initially before decreasing when mineralization has far 
progressed; BSP is momentarily expressed at an early stage and then 
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upregulated again during bone formation by differentiated osteoblasts; and 
osteocalcin is associated with mineralization (Aubin, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
As ALP is one of the earliest markers of osteoblastic cell differentiation (Choi et 
al, 2011), the active expression of this marker in our study, specifically in M-
cMSCs, on day 7 showed their responsiveness to the initiation of osteogenic 
differentiation. Additionally, on day 14, M-cMSCs displayed a statistically 
significant upregulation of ALP compared with F-cMSCs (p<0.05). As expected, 
both cell types displayed maximal ALP expression levels on day 7 before the 
slight decline on day 14. A similar trend was displayed also by BSP expression 
levels. 
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Figure 37 Osteogenic differentiation in vitro and expression of bone markers at 
different periods. 
DNA 
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Osteocalcin is an important non-collagenous protein component of bone 
extracellular matrix, it is considered indicator of osteoblast differentiation, and it is 
produced and secreted by osteoblast in the late stage of maturation (Sila-Asna et 
al, 2007; Kaveh et al, 2011). Accordingly, our observations demonstrated a 
significant OC upregulation from M-cMSCs relative to F-cMSCs, and this 
increase was more pronounced at 14 days of induction of mandible cells. 
There were no changes at days 7 and 14 for both types of cMSCs, and 
compared with the cells under non-induced media with regards to the expression 
of OPN. This data could be due to possible presence of intracellular OPN. It was 
first reported by Zohar et al (Zohar et al, 1997) in osteogenic cultures of fetal rat 
calvarial cells. During MSC differentiation, as intracellular OPN has an effect on 
the activation of mitogen-activated protein kinase (MAPK) signaling; it is possible 
that OPN has effect on MSCs survival and differentiation.  
In vitro osteogenic differentiation of MSCs fundamentally depends on the culture 
conditions. Two common components of osteogenic induction medium are bone 
morphogenetic proteins (BMPs) and glucorticoids particularly, dexamethasone. 
Apparently, MSC responsiveness to osteogenic inducers is specie-specific. . 
According to Volk et al (Volk et al, 2005), BMPs are effective inducers cMSC 
osteogenesis.. On the other hand, dexamethasone looks to have no 
osteoinductive effect and reduces BMP-stimulated osteogenesis. Moreover, the 
addition of ascorbate which promotes formation of a collagen-rich matrix, to 
BMP-containing medium seems to be necessary when MSCs from young dogs 
are used. In this study, the authors found that combination of BMP and ascorbate 
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resulted in a significant increase of ALP activity, whereas the combination of 
dexamethasone and ascorbate was unsuccessful in inducing osteogenesis. 
These findings are consistent with our first set of osteogenesis trials where we 
used medium containing dexamethasone and ascorbate and the expression of 
ALP and BSP were not increased in mandible and femur MSCs compared with 
the cells maintained under non-osteogenic conditions (data not shown). But 
switching to BMP-containing osteogenic medium thereafter improved osteogenic 
responsiveness of cMSCs.. 
In vivo osteogenesis of cMSCs 
While in vitro osteogenesis of M-cMSCs was apparently higher than that of F-
cMSCs, there were no site-related differences in in vivo bone formation by both 
cell type whether induced osteogenically or not. In a study by Kang et al (Kang et 
al, 2012), where osteogenic potential of cMSCs from adipose tissue, bone 
marrow, umbilical cord blood, and Wharton’s jelly were compared, it was found 
that the in vitro  osteogenic potential presented differences among the cell types 
without any significant differences in bone formation in vivo. These outcomes 
suggest the osteogenic potential observed in vitro and in vivo can be slightly 
different for each type of MSCs. This hypothesis is supported by Cho et al (Cho 
et al, 2010) who found discrepancies of differentiation potential between in vitro 
and in vivo results of differentiation in several types of MSCs. 
Tissue vascularization plays a vital role in osteogenesis to support 
osteoprogenitor cell survival.(Kang et al, 2012). On the other hand, the formation 
of blood vessels can be induced by the initial presence of MSCs (Kaigher et al, 
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2003) because MSCs also secrete vascular endothelial growth factor (VEGF) 
that plays a central role in angiogenic response. Kang et al (Kang et al, 2012) 
speculated that the results obtained in the in vivo assay where new bone 
formation was similar in different types of MSCs, could be influenced by the 
capacity of MSCs to promote neovascularization. Furthermore, the biochemical 
and mechanical factors affecting the destiny of MSCs in their stem cell niche are 
different from those used in the in vitro techniques (Birmingham et al, 2012). 
While the functions of the inducers during osteogenesis in vitro has been 
elucidated (Vater et al, 2011), the in vivo biochemical environment and the 
driving source for the osteogenic differentiation of MSCs in their native habitat 
remains unclear (Birmingham et al, 2012). 
Adipogenic differentiation 
Adipogenic differentiation was confirmed by the presence of Oil Red O stained 
lipid vacuoles within cells cultured in adipogenic medium. These observations are 
consistent with previous reports of cMSCs (Vieira et al, 2010; Csaki et al, 2007, 
Kisiel et al, 2012). Cells from the mandible area seemed to have greater 
adipogenic potential based on a subjectively greater number of lipid clusters 
within the cells, compared with cells from femur. This is in contrast to the study 
by Akintoye et al (Akintoye et al, 2006) where human MSCs from appendicular 
bone such as iliac crest showed a more pronounced differentiation to adipocytes 
compared with cells from the orofacial area (maxilla and mandible). Other studies 
(Seo et al, 2009: Neupane et al, 2008) have reported the inability of isolated and 
cultured cMSCs, in one case from adipose tissue and from umbilical cord blood 
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in the other, to differentiate towards the adipogenic lineage. In the study by 
Neupane et al (Neupane et al, 2008), cMSCs were found to be refractory to the 
commonly used adipogenic induction media for human MSCs. After replacement 
of fetal bovine serum with rabbit serum and addition of higher glucose 
concentration to the medium, adipogenic differentiation was enhanced. As 
demonstrated by Csaki et al (Csaki et al, 2007), in our study, adipogenesis was 
induced with insulin, dexamethasone and 1-methyl-3-isobutylxanthine (IBMX). 
Some investigators (Gregoire et al, 1998)  have proposed that although the full 
complement of inducing agents required for differentiation varies with each cell 
culture model, insulin/insulin-like growth factor I (IGF-I), cyclic adenosine 
monophosphate and glucocorticoids are generally considered necessary for the 
induction of adipogenic differentiation either in serum-containing or in serum-free 
media. 
Chondrogenic differentiation 
Our attempt at differentiating cMSCs into the chondrogenic lineage using 
induction medium with TGFβ-3 was considered successful. Recovery of the cell 
pellet culture after 4 and 8 weeks followed by Alcian blue staining revealed 
intense staining of a high content of cartilage specific proteoglycans. The 
presence of chondrocytes was noticed by pink or red staining of their respective 
nuclei and the cells adopting rounded shape. Similar findings were described by 
Csaki et al (Csaki et al, 2007), where they induced chondrogenic differentiation in 
bone marrow-derived MSCs. In contrast to this, control cultures showed little or 
no alcian blue staining. Despite these results, Kisiel et al (Kisiel et al, 2012) 
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reported unsuccessful attempts at differentiating cMSCs from different tissues 
along the chondrogenic lineage. It would be interesting to validate the expression 
pattern of genes associated with chondrogenic markers such as collagen type II, 
aggrecan, and sex-determining region Y box 9 (SOX9) to confirm differentiation 
of cMSCs towards chondrogenesis when morphological and histochemical 
results remain inconclusive (Neupane et al, 2008; Seo et al, 2012; Volk et al, 
2012, Vieira et al, 2010). In our study, the addition of dexamethasone and TGFβ-
3 to the chondrogenic medium played an important role in chondrogenesis: 
TGFβ-3 works by upregulating the expression of extracellular matrix genes 
(Dong et al, 2005), and dexamethasone, by also increasing the expression of 
extracellular matrix genes and/or enhancing their TGFβ-3 –mediated expression 
(Derfoul et al, 2006) 
Neurogenesis differentiation 
In our study, cMSCs were induced neurogenically for different time points 
ranging from 24 hours to 4, 7, and 14 days to assess how soon they promote 
formation of neuronal precursor cells. As previously reported (Kim et al, 2014; 
Jang et al, 2010.) we used the two-step neurogenic induction protocol: the first 
step was preinduction with fetal bovine serum and β-fibroblast growth factor (β-
FGF); the second step was induction phase with medium supplemented with 
butylated hydroxyanisole (BHA), forskolin, valproic acid, and insulin. The purpose 
of these two steps is to decrease environmental damage to cells after adding 
supplemented medium for neuronal induction (Kim et al, 2014). Previous studies 
have used numerous reagents to differentiate neural precursor cells such as 
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dibutyryl-cyclic adenosine monophosphate (db-cAMP), 3-isobutyl-1-
methylxanthine (IBMX), and retinoic acid (RA) (Tio et al, 2010); a cocktail of 
IBMX, indomethacin, and insulin (Fujimura et al, 2005); neural growth factor 
(Kamishina et al, 2008), and β-FGF and forskolin (Jang et al, 2010). IBMX and 
db-cAMP upregulate intracellular cAMP levels, which possibly activate protein 
kinase A (PKA). Wang et al (Wang et al, 2007) stated that PKA mediates neural 
differentiation of human cord blood-derived MSCs. β-FGF has a substantial 
capacity for neuronal differentiation by producing neuronal precursor cells. 
Forskolin is a regularly used agent to upregulate the intracellular levels of cAMP, 
which eventually activates the protein kinase A (PKA) signaling pathway. 
Additionally, forskolin induces the neuron-like morphology and expression of 
some neural specific genes in human MSCs (Jang et al, 2010). 
The observed neuronal-like morphological changes in the induced cMSCs were 
consistent with previous studies on cMSCs (Oda et al, 2013; Kamishina et al, 
2006),   umbilical cord blood and amniotic membrane-derived cMSCs (Seo et al, 
2009-Q; Park et al, 2012). In fact, Kamishina et al (Kamishina et al, 2006) 
reported that cMSCs had neuron-like morphologic characteristics as early as 3 
hours after the induction of neural differentiation. The interpretation of the 
significance of these in vitro neuronal changes should not be overestimated as 
previously mentioned by other researchers (Lu et al, 2004; Neuhiber et al, 
2004),. These investigators have expressed that the morphological and 
immunocytochemical changes observed after neuronal induction could be the 
result of cytotoxic effects of the reagents in the induction medium, which leads to 
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cell shrinkage and actin cytoskeleton retraction. Also, these changes might be a 
response to chemical stress, because similar cellular modifications have been 
observed in the presence of Triton X-100 or sodium hydroxide (Deng et al, 2006).  
We also analyzed the neural-specific proteins nestin and βIII-tubulin by 
immunostaining and found that both non-induced and induced cMSCs expressed 
these neuron-specific markers. The spontaneous expression of these neural-
specific proteins by cMSCs, under normal culture conditions has also been 
previously reported. Deng et al (Deng et al, 2006) found that nearly 100% of mice 
MSCs cultures spontaneously expressed the intermediate filament protein nestin, 
In addition, the cells in their study were also positive for several neuron-specific 
proteins, including βIII-tubulin and medium weight neurofilament (NFM), but 
negative for the astrocyte-specific glial fibrillary acidic protein (GFAP) and 
vimentin. Kamishina et al (Kamishina et al, 2006), studying neuronal 
differentiation of cMSCs from iliac crest bone marrow, found that 
immunocytochemical and western blot analyses revealed that untreated cMSCs 
strongly expressed βIII-tubulin and GFAP. The authors concluded that, if cMSCs 
are positive for βIII-tubulin, they probably have inherent potential to differentiate 
into neuronal cells under appropriate conditions. 
The spontaneous attainment of neural properties by non-induced MSCs. may be 
explained by the neural differentiation propensity of stem cell reflected in the 
development of the nervous system during embryogenesis. Undetermined 
ectoderm cells differentiate into neural lineage by default unless inhibited by 
ventralizing factors, such as bone morphogenetic protein-4 (BMP4) (Wilson and 
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Hemmati-Brivanlou 1995). Therefore, it is likely that MSCs, as multipotent stem 
cells, may exhibit a neural property in their default state of differentiation in vitro, 
where there are no pro-mesoderm inhibitors such as BMP4 (Deng et al,  2006). 
Since our studies show inconsistencies in site-specific neuronal differentiation of 
cMSCs, it will be more informative to examine this further at the genetic level and 
with longer induction periods.  
 
6 CONCLUSIONS 
Dogs offer not only a valuable experimental model but also represent a clinically 
relevant and superior animal model compared with other organisms. Previous 
studies have successfully isolated cMSCs from different tissues, and in vitro 
differentiation capacities have also been reported. Undifferentiated cMSCs have 
been characterized morphologically, immunophenotypically, and by their gene 
expression. However, in marked contrast with human MSCs, basic biology of 
cMSCs is yet to be fully elucidated, and so far no uniform characterization criteria 
are available for MSCs from canine origin. Only a limited number of trials have 
attempted to identify a panel of cell surface markers and transcription factor 
profiles for these stem cells. While the current study tested cMSCs from a 
restricted number of subjects, it enhanced our understanding of cMSCs and their 
skeletal site-specific characteristics. Our results demonstrated that cryopreserved 
cMSCs could be expanded and differentiated, in vitro, at least into the three main 
differentiation lineages: osteogenic, adipogenic, and chondrogenic, as well as 
neurogenic. In addition, the impressive osteogenic potential of cMSCs, in this 
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study also showed that M-cMSCs are apparently more responsive to multi-
lineage differentiation relative to F-cMSCs. These are consistent with data from 
studies using human, mouse and rat MSCs (Akintoye et al, 2006; Yoshimura et 
al, 2007; Aghaloo et al, 2010; Lee et al, 2011).  
One prospective future direction is to confirm these results by using a larger 
population of MSC donors; therefore, the inter-animal variability would be 
minimized. Since dog breeds exhibit an extremely wide range of body types, it 
would be interesting to research MSCs from different canine breeds. Another 
avenue of investigation of cMSCs would be the refinement of in vitro expansion 
strategies as well as detailed comprehension of donor characteristics. Future 
pre-clinical and clinical studies regarding cMSCs is definitely required not only to 
motivate, but also to appropriately translate the potential therapeutic use of these 
cells in both veterinary and human medicine. 
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